[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 94 of about 94
1. Picozzi VJ, Pohlman BL, Morrison VA, Lawless GD, Lee MW, Kerr RO, Ford JM, Delgado DJ, Fridman M, Carter WB: Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma. Oncology (Williston Park); 2001 Oct;15(10):1296-306; discussion 1310-1, 1314
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.
  • Records from 653 patients treated between 1991 and 1998 in the Oncology Practice Patterns Study (OPPS) were analyzed to determine contemporary chemotherapy delivery patterns in patients with intermediate-grade non-Hodgkin's lymphoma (NHL).
  • Of the 653 patient records reviewed, 90 (14%) omitted an anthracycline or mitoxantrone (Novantrone) from primary therapy.
  • Of 181 advanced-stage patients with responsive disease, 28 (15%) failed to receive at least six treatment cycles.
  • Overall, 283 (43%) of 653 patients potentially received suboptimal chemotherapy due either to choice of regimen or chemotherapy delivered.
  • Patient age > or = 65 years and cardiac comorbidity appeared to have the greatest influence on a physician's decision regarding chemotherapy administration.
  • Among the 492 patients who received CHOP or CNOP, 235 (48%) experienced a delay or reduction in chemotherapy dose (usually neutropenia-related), 100 (20%) developed mucositis, and 116 (24%) were hospitalized for febrile neutropenia.
  • This assessment of chemotherapy delivery to patients with intermediate-grade NHL showed significant variation from current standards.
  • Further analysis of factors influencing chemotherapy delivery might improve therapeutic outcomes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Growth Substances / therapeutic use. Humans. L-Lactate Dehydrogenase / analysis. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Neutropenia / chemically induced. Prednisolone / administration & dosage. Prednisolone / adverse effects. Prednisone / administration & dosage. Prednisone / adverse effects. Reference Values. Retrospective Studies. Severity of Illness Index. Time Factors. Vincristine / administration & dosage. Vincristine / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11702959.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Growth Substances; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone; CHOP protocol; MCOP protocol
  •  go-up   go-down


2. Blayney DW, McGuire BW, Cruickshank SE, Johnson DH: Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma. Oncologist; 2005 Feb;10(2):138-49
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
  • Dose densification and dose escalation of cytotoxic chemotherapy may be important in improving the cure rates of chemotherapy-responsive cancers.
  • We conducted two phase I studies, in non-small cell lung cancer (NSCLC) and in lymphoma, to explore the possibility of intensifying chemotherapy by compressing the delivery of and escalating the dose of standard combination chemotherapy.
  • One study used etoposide and cisplatin chemotherapy in patients with unresectable stage III or IV NSCLC, intensifying chemotherapy by reducing the cycle length.
  • The second study used cyclophosphamide, doxorubicin, vincristine, and prednisone, CHOP chemotherapy, in the treatment of stage II-IV intermediate or immunoblastic high-grade lymphoma, intensifying chemotherapy first by reducing the cycle length and then by escalating the dosages of cyclophosphamide and doxorubicin.
  • Fifty-five patients with NSCLC and 49 with non-Hodgkin's lymphoma (NHL) were enrolled and treated in successive cohorts.
  • At standard dosages and intervals of chemotherapy, filgrastim support resulted in incidences of grade 3 and 4 neutropenia that were between 62% and 77% lower than those in the no-filgrastim control; the mean duration of neutropenia was, likewise, more than 80% lower.
  • In the NSCLC trial, etoposide and cisplatin were intensified by >50%, and in the lymphoma trial, cyclophosphamide was intensified by 270% and doxorubicin was intensified by 87%.
  • Chemotherapy reductions or delays for neutropenia were rare in the groups receiving filgrastim; but at higher chemotherapy intensities, dose-limiting thrombocytopenia was encountered.
  • We conclude that the delivery of myelosuppressive chemotherapy in both a dose-intense and a dose-dense manner is feasible with filgrastim support.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Prednisone / administration & dosage. Prednisone / adverse effects. Recombinant Proteins. Thrombocytopenia / chemically induced. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709216.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; PVI5M0M1GW / Filgrastim; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone
  •  go-up   go-down


3. Chen CI, Roitman D, Tsang R, Stewart AK, Keating A, Crump M: 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant; 2002 Dec;30(12):885-91
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
  • The purpose of the study was to assess the impact of number of salvage regimens needed to demonstrate chemotherapy sensitivity on relapse rates, survival, and toxicity following high-dose therapy and autologous bone marrow transplantation (ABMT) in relapsed or refractory non-Hodgkin's lymphoma.
  • We retrospectively reviewed 136 patients with intermediate-grade lymphoma who underwent ABMT.
  • All patients were treated with salvage therapy to maximum tumor reduction.
  • When compared to patients requiring >or= two regimens, patients requiring only one salvage regimen to demonstrate chemosensitivity were more likely to have a longer previous CR from initial therapy (CR >or=12 months in 47% vs 26%; P = 0.04) and to have attained CR with salvage (54% vs 16%; P = 0.001).
  • Time to engraftment, toxic deaths and incidence of myelodysplasia were similar in the groups.
  • The survival rate observed in patients requiring >or=two salvage regimens, although inferior to that of patients receiving a single salvage regimen, are still generally superior to results in the literature for patients treated with chemotherapy alone without ABMT.
  • We conclude that high-dose therapy with ABMT is appropriate for lymphoma patients even when disease reduction requires repeated numbers of salvage regimens.
  • [MeSH-major] Bone Marrow Transplantation. Drug Resistance, Neoplasm. Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation. Salvage Therapy / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Life Tables. Male. Middle Aged. Recurrence. Retrospective Studies. Survival Analysis. Transplantation Conditioning / adverse effects. Transplantation, Autologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12476281.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Gobbi PG, Ghirardelli ML, Avanzini P, Baldini L, Quarta G, Stelitano C, Broglia C, Loni C, Silingardi V, Ascari E: A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL). Haematologica; 2000 Mar;85(3):263-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
  • BACKGROUND AND OBJECTIVE: The positive results of high-dose chemotherapy followed by rescue with bone marrow progenitor cell transplantation are generally ascribed to the high dose size (DS) of the drugs given.
  • With the aim of comparing the role of DS and DI in non-Hodgkin's lymphomas, a variant of Fisher's ProMACE-CytaBOM regimen was designed in which the projected cumulative drug DIs remained the same as in the original schedule but the DSs were tripled.
  • Thirty-six outpatients with intermediate- and high-grade non-Hodgkin's lymphomas entered the pilot study; 29 were untreated and 7 had relapse disease.
  • RESULTS: Of the 29 previously untreated patients, 16 achieved complete remission, 8 partial remission, 4 developed progressive disease and 1 was withdrawn early from the study because of acute viral hepatitis; subsequently 4 relapsed and 3 died (2 of disease progression, 1 of causes unrelated to the disease).
  • In the pre-treated group 3 patients obtained complete remission, 2 partial remission and in 1 patient the disease progressed; 3 of these pre-treated patients died (1 of progressive disease, 1 of a new relapse, 1 of myocardial infarction during therapy).
  • Grade 3-4 hematologic toxicity consisted of anemia in 3 cases, of leukopenia in 8 and of thrombocytopenia in 2; the same grade of non-hematologic toxicity involved the liver in 2 cases, the heart in 1 (the above mentioned death), the digestive mucosa in 2 and the peripheral nerves in 1 patient.
  • INTERPRETATION AND CONCLUSIONS: The iso-DI sequential variant of the ProMACE-CytaBOM regimen can be considered feasibile, relatively non-toxic, and can be given on an out-patient basis.
  • Limited use of G-CSF is required (about 3 vials after each drug administration).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Anemia / chemically induced. Bleomycin / administration & dosage. Bleomycin / toxicity. Cyclophosphamide / administration & dosage. Cyclophosphamide / toxicity. Cytarabine / administration & dosage. Cytarabine / toxicity. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / toxicity. Etoposide / administration & dosage. Etoposide / toxicity. Female. Humans. Italy. Male. Methotrexate / administration & dosage. Methotrexate / toxicity. Middle Aged. Pilot Projects. Prednisone / administration & dosage. Prednisone / toxicity. Recurrence. Survival Rate. Vincristine / administration & dosage. Vincristine / toxicity

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10702814.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] ITALY
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; PROMACE-CytaBOM protocol
  •  go-up   go-down


5. Chau I, Webb A, Cunningham D, Hill M, Rao S, Ageli S, Norman A, Gill K, Howard A, Catovsky D: An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br J Haematol; 2001 Dec;115(4):786-92
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma.
  • This study was designed to assess the efficacy and safety of substituting cisplatin with oxaliplatin in the DHAP (dexamethasone, cytarabine and cisplatin) regimen for patients with relapsed or refractory non-Hodgkin's lymphoma.
  • Twenty-four evaluable patients with intermediate or high-grade non-Hodgkin's lymphoma were treated at 3-weekly intervals with oxaliplatin (130 mg/m2, d 1), cytarabine (2 g/m2 for two doses, d 2) and dexamethasone (40 mg, d 1-4).
  • Grade 3 and 4 toxicity was mainly haematological: anaemia 17%, neutropenia 75% and thrombocytopenia 75%.
  • No grade 4 non-haematological toxicity was reported.
  • In conclusion, dexamethasone, cytarabine and oxaliplatin (DHAX) is a novel combination in salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
  • Lack of renal toxicity makes DHAX an attractive cytoreductive regimen before high-dose chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Organoplatinum Compounds / therapeutic use. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Female. Hematopoietic Stem Cell Transplantation. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large-Cell, Anaplastic / drug therapy. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, T-Cell, Peripheral / drug therapy. Male. Middle Aged. Transplantation, Autologous. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11843810.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04079A1RDZ / Cytarabine; 04ZR38536J / oxaliplatin; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


6. Raina V, Sharma A, Vora A, Shukla NK, Deo SV, Dawar R: Primary gastrointestinal non Hodgkin's lymphoma chemotherapy alone an effective treatment modality: experience from a single centre in India. Indian J Cancer; 2006 Jan-Mar;43(1):30-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal non Hodgkin's lymphoma chemotherapy alone an effective treatment modality: experience from a single centre in India.
  • BACKGROUND: Gastrointestinal tract (GI) is the most frequently involved extra nodal site in non-Hodgkin's lymphoma (NHL).
  • Surgery, radiotherapy and chemotherapy (CT) have been used mostly in various combinations, but lately chemotherapy alone has emerged as an effective option.
  • The purpose of this study is to evaluate efficacy of CT alone in treatment of primary GI-NHL and to compare the results with combined CT+surgery.
  • SETTING AND DESIGN: Retrospective analysis of case records of GI NHL patients.
  • MATERIALS AND METHODS: Over a 15-year period (1986-2000), 77 new cases of primary GI-NHL were registered at our center.
  • GI-NHL was defined according to standard criteria.
  • All patients received chemotherapy.
  • Laparotomy was done in 58% (45) of patients to establish a diagnosis or as primary or debulking treatment.
  • Seventy eight percent of tumors were intermediate to high grade, 43% (33) received only CT while 57% (44) received CT+surgery.
  • CONCLUSION: Organ-preservation strategy using chemotherapy alone (CT) can be successfully employed in a significant number of patients with primary GI-NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrointestinal Neoplasms / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Female. Humans. India / epidemiology. Laparotomy. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16763360.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


7. Frohlich DE, Chen JL, Neuberg D, Kehoe KM, Van den Abbeele AD: When is hilar uptake of 67Ga-citrate indicative of residual disease after CHOP chemotherapy? J Nucl Med; 2000 Feb;41(2):269-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] When is hilar uptake of 67Ga-citrate indicative of residual disease after CHOP chemotherapy?
  • The purpose of this study was to evaluate the prevalence and characterize the patterns of hilar uptake (HU) on 67Ga-citrate imaging after cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimens for non-Hodgkin's lymphoma (NHL), to differentiate hilar lymphoma (HL) from HU of benign etiology.
  • METHODS: A total of 930 studies (698 planar, 232 thoracic SPECT) was reviewed retrospectively in 100 NHL patients (29 low-grade, 60 intermediate-grade, and 11 high-grade) treated with CHOP and followed up longitudinally with serial gallium studies (planar: median, 7; range, 3-16 studies in 100 patients; SPECT: median, 1; range, 0-11 studies in 72 patients) over a median duration of 36 mo (range, 6-112 mo) from diagnosis.
  • Clinical outcome and size changes over time on correlative CT and/or radiographs were used to evaluate benign versus malignant changes within the hila.
  • The prevalence of HU and HL at various time points was as follows: baseline HU, 52% with HL 60%; mid-CHOP HU, 59% with HL2%; post-CHOP HU, 52% with HL6%; follow-up HU, 76% with HL 9%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Citrates. Gallium. Gallium Radioisotopes. Lung / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging. Tomography, Emission-Computed, Single-Photon
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm, Residual. Predictive Value of Tests. Prednisone / administration & dosage. Retrospective Studies. Time Factors. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. GALLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10688110.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Citrates; 0 / Gallium Radioisotopes; 27905-02-8 / gallium citrate; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CH46OC8YV4 / Gallium; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


8. Miglino M, Santini G, Grasso R, Pietrasanta D, Clavio M, Pierri I, Canepa L, Nati S, Ballerini F, Varaldo R, Palmisano G, Gobbi M: Molecular analysis of patients with relapsed or refractory intermediate-high grade non-Hodgkin's lymphoma with bone marrow infiltration undergoing peripheral blood progenitor cell transplantation. Haematologica; 2001 Jul;86(7):706-14
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular analysis of patients with relapsed or refractory intermediate-high grade non-Hodgkin's lymphoma with bone marrow infiltration undergoing peripheral blood progenitor cell transplantation.
  • We have developed a three-step single strand conformational polymorphism PCR strategy which is able to detect clonal B lymphoid cells at a frequency as low as 1 clonal cell in 10(6) normal cells.
  • DESIGN AND METHODS: Twenty patients with intermediate or high-grade B non-Hodgkin's lymphoma (NHL) were evaluated.
  • Patients were pre-treated with a median of two (range 1-4) conventional chemotherapy lines before high-dose cyclophosphamide (HDCY).
  • Nineteen patients were offered high-dose therapy followed by peripheral blood progenitor cells (PBPC) autografting.
  • RESULTS: MRD analysis was performed for each patient at the end of conventional chemotherapy and every three months after high dose therapy.
  • All these patients achieved complete response (CR) after high dose therapy (HDT).
  • Six patients relapsed after a median time of 24.5 months.
  • INTERPRETATION AND CONCLUSIONS: Whereas the detection of clonal cells in the apheresis samples did not predict an unfavorable outcome, the disappearance of the clonal rearranged band from the BM sample after HDT proved to be a favorable prognostic factor and was associated with long-lasting disease-free status
  • [MeSH-major] Bone Marrow / pathology. Hematopoietic Stem Cell Transplantation. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Adult. Female. Gene Rearrangement. Humans. Immunoglobulin Heavy Chains / genetics. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm, Residual / diagnosis. Neoplasm, Residual / genetics. Neoplasm, Residual / pathology. Prognosis. Prospective Studies. Recurrence. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11454525.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


9. Raida L, Papajík T, Indrák K, Herman M, Paucek B, Zapletalová J: [Chemotherapy of BOVAPEC in the primary treatment of Hodgkin's lymphoma intermediate stages]. Vnitr Lek; 2007 Jan;53(1):31-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy of BOVAPEC in the primary treatment of Hodgkin's lymphoma intermediate stages].
  • [Transliterated title] Chemoterapie BOVAPEC v primární lécbe stredne pokrocilých stadií Hodgkinova lymfomu.
  • DESIGN: Chemotherapy of BOVAPEC is the modification of temporary intensified Stanford V protocol, an effective primary treatment of advanced Hodgkin's lymphoma (HL) in spite of limited toxicity.
  • Nitrogen mustard was substituted by less myelotoxic cyclophosphamide and the protocol has been used in the treatment of patients with an intermediate stage of HL.
  • METHODS: The primary treatment with BOVAPEC was started in 62 patients.
  • Complete chemotherapy schedule was administered to 60 patients (97%) and the median of its overall duration was 13 (12-18) weeks.
  • RESULTS: During the treatment, a neutropenia of grade 3 and 4 was observed in 14 patients (23%) but without the development of any serious infectious complications.
  • The manifestation of early non-hematological toxicity did not overcome grade 2.58 patients (94%) achieved the complete remission of HL.
  • The combination of BOVAPEC and RT in primary treatment was associated with higher probability of five years DFS but actually without statistical significance (88% vs. 58%; p = 0.08).
  • CONCLUSION: The BOVAPEC regimen with its acceptable toxicity may represent effective primary therapeutic approach to the patients with the intermediate stage of HL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / adverse effects. Bleomycin / therapeutic use. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Male. Middle Aged. Prednisolone / adverse effects. Prednisolone / therapeutic use. Vinblastine / adverse effects. Vinblastine / therapeutic use. Vincristine / adverse effects. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vnitr Lek. 2007 Jan;53(1):7-8 [17472009.001]
  • (PMID = 17472013.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BOVAPEC protocol
  •  go-up   go-down


10. Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M, OPPS Working Group, ANC Study Group: Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma; 2003 Dec;44(12):2069-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy.
  • We sought to identify risk factors associated with the time to febrile neutropenia in patients with intermediate-grade, non-Hodgkin's lymphoma (NHL) who were receiving treatment with CHOP chemotherapy.
  • We reviewed the medical records of 577 intermediate-grade NHL patients who received initial CHOP chemotherapy and evaluated risk factors associated with time to first febrile neutropenic event.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Fever / etiology. Lymphoma, Non-Hodgkin / drug therapy. Neutropenia / etiology. Prednisolone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Body Temperature. Cardiovascular Diseases / complications. Colony-Stimulating Factors / metabolism. Female. Hemoglobins / metabolism. Humans. Kidney Diseases / complications. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Risk. Risk Factors. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Fever.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14959849.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Colony-Stimulating Factors; 0 / Hemoglobins; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


11. Chua SL, Seymour JF, Streater J, Wolf MM, Januszewicz EH, Prince HM: Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma; 2002 Sep;43(9):1783-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma.
  • Central nervous system (CNS) relapse of non-Hodgkin's lymphoma (NHL) is usually fatal despite therapy and effective prophylaxis is desirable.
  • We therefore analyzed the outcome of all patients with newly diagnosed "intermediate-grade" NHL receiving i.t. prophylaxis from 1991 to 1999.
  • Anthracycline-based chemotherapy was used in all cases and included high-dose methotrexate +/- ara-C in six patients.
  • The median number of i.t. treatments was 5 (range 1-12) and comprised methotrexate +/- steroid in 15, together with ara-C in 11.
  • Treatment-related variables associated with higher CNS-relapse rates (34-50%) were: delay of > or = 14 days from diagnosis to first i.t. injection, < 5 i.t. treatments, delay of i.t. prophylaxis until after attaining CR and systemic treatment lacking high-dose methotrexate +/- ara-C (each P < or = 0.17). I.t.
  • [MeSH-major] Central Nervous System Neoplasms / prevention & control. Injections, Spinal. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / therapeutic use. Female. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Prognosis. Risk Factors. Secondary Prevention. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12685832.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


12. Kinoshita T, Hotta T, Tobinai K, Kobayashi T, Ishizuka N, Tomonaga M, Sai T, Ohno Y, Kasai M, Ogura M, Mikuni C, Toki H, Sano M, Masaki Y, Ohtsu T, Matsuno Y, Takenaka T, Shirakawa S, Shimoyama M, Japan Clinical Oncology Group: A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002. Int J Hematol; 2004 Nov;80(4):341-50
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002.
  • The effect of enhancing the dose intensity (DI) of the key drugs in multidrug combination chemotherapy for malignant lymphoma is uncertain.
  • We investigated the survival benefit of dose-intensified multidrug combination chemotherapy for intermediate- or high-grade non-Hodgkin's lymphoma (NHL).
  • Patients without any prior chemotherapy were randomly assigned either to dose-intensified multidrug combination chemotherapy, LSG9 (VEPA-B/FEPP-AB/M-FEPA, treated 3 times every 10 weeks for 28 weeks total), or to control-arm combination chemotherapy, mLSG4 (VEPA-B/FEPP-B/M-FEPA, treated 4 times every 14 weeks for 54 weeks total).
  • The planned DI of doxorubicin and cyclophosphamide were 1.96 and 1.47 times higher, respectively, in LSG9 than in mLSG4.
  • The median actual DI of doxorubicin and cyclophosphamide were 1.56 and 1.17 times higher, respectively, in LSG9 than in mLSG4.
  • An increase in the DI of doxorubicin in multidrug combination chemotherapy did not improve the survival of patients with intermediate- or high-grade NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Prednisolone / administration & dosage. Vincristine / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Ann Oncol. 1999 May;10(5):519-25 [10416000.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1341-6 [12196358.001]
  • [Cites] Ann Intern Med. 1985 May;102(5):596-602 [2580468.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1188-95 [3897470.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1287-95 [15044639.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3025-30 [10944137.001]
  • [Cites] Eur J Haematol. 1996 Nov;57(5):377-83 [9003479.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):777-80 [9743300.001]
  • [Cites] Semin Oncol. 1987 Mar;14(1):65-74 [3823917.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):25-38 [1702144.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1241-7 [11106111.001]
  • [Cites] N Engl J Med. 1997 May 1;336(18):1290-7 [9113932.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1023-30 [8450856.001]
  • [Cites] Ann Intern Med. 1986 Jun;104(6):757-65 [2422995.001]
  • [Cites] Int J Hematol. 2002 Dec;76(5):385-93 [12512832.001]
  • [Cites] Ann Oncol. 1999 Sep;10(9):1079-86 [10572606.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):769-78 [7512131.001]
  • [Cites] Clin Cancer Res. 1998 Sep;4(9):2027-37 [9748116.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2796-802 [9704732.001]
  • [Cites] J Clin Oncol. 1990 Jun;8(6):963-77 [2348230.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1347-55 [12196359.001]
  • [Cites] N Engl J Med. 1992 Nov 5;327(19):1342-9 [1383819.001]
  • [Cites] Int J Hematol. 2002 Dec;76(5):411-9 [12512835.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] N Engl J Med. 1995 Apr 20;332(16):1045-51 [7898521.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] N Engl J Med. 1993 Dec 9;329(24):1770-6 [7694148.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2472-9 [12011124.001]
  • [Cites] J Clin Oncol. 1991 Feb;9(2):339-47 [1824863.001]
  • [Cites] Cancer. 1979 Feb;43(2):417-25 [84706.001]
  • [Cites] J Natl Cancer Inst. 1998 Aug 19;90(16):1205-11 [9719081.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2916-23 [8523055.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 Feb;21(2):175-9 [3886392.001]
  • [Cites] Cancer. 1994 Oct 1;74(7):1939-44 [7521788.001]
  • [Cites] Br J Cancer. 1996 Jul;74(2):318-22 [8688344.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • (PMID = 15615259.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VEPA-B protocol
  •  go-up   go-down


13. Morrison VA, Picozzi V, Scott S, Pohlman B, Dickman E, Lee M, Lawless G, Kerr R, Caggiano V, Delgado D, Fridman M, Ford J, Carter WB, Oncology Practice Pattern Study Working Group: The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma; 2001 Jun;2(1):47-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis.
  • The purpose of this historical case series study was to evaluate the association of age on delivered dose intensity of initial CHOP (cyclophosphamide/doxorubicin/ vincristine/prednisone) chemotherapy and the occurrence of hospitalizations for febrile neutropenia for patients with intermediate-grade non-Hodgkin's lymphoma (NHL).
  • Medical records of 930 NHL patients not enrolled on clinical trial protocols were reviewed.
  • We reported on 577 of the study patients (62%) who received initial CHOP chemotherapy.
  • In patients with advanced-stage NHL (stage III/IV), older patients received fewer cycles of CHOP (< 6 cycles, 35% vs. 22%; P < 0.05) than younger patients.
  • Multiple logistic regression models showed that older patients were more likely to receive a lower dose intensity (ARDI < or = 80%; odds ratio = 2.46, 95% confidence interval [CI]: 1.62-3.72) during their first 3 cycles of therapy and to experience more hospitalizations for febrile neutropenia (odds ratio = 2.17, 95% CI: 1.43-3.30).
  • We found the dose intensity of delivered CHOP chemotherapy for elderly patients to be less than standard CHOP therapy and the risk of hospitalizations for febrile neutropenia to be greater than in younger patients.
  • Prospective clinical trials examining supportive care measures, such as colony-stimulating factor, for elderly NHL patients are recommended.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fever / chemically induced. Lymphoma, Non-Hodgkin / drug therapy. Neutropenia / chemically induced
  • [MeSH-minor] Adult. Age Factors. Aged. Cyclophosphamide / administration & dosage. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Hospitalization. Humans. Male. Middle Aged. Odds Ratio. Prednisone / administration & dosage. Retrospective Studies. Risk Factors. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Fever.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707870.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


14. Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, Scadden D, Kaplan L, Ambinder R, Levine A, Harrington W, Grochow L, Flexner C, Tan B, Straus D, AIDS Malignancy Consortium: Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol; 2001 Apr 15;19(8):2171-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
  • PURPOSE: This study investigated the efficacy, toxicity, and pharmacokinetic interactions resulting from simultaneous combination chemotherapy and highly active antiretroviral therapy (HAART) for patients with human immunodeficiency virus (HIV)-associated non-Hodgkin's lymphoma (NHL).
  • In addition, the effects on viral load, CD4 counts, and opportunistic infections were examined with the use of combination chemotherapy combined with HAART.
  • PATIENTS AND METHODS: Sixty-five patients with previously untreated and measurable disease at any stage of HIV-associated NHL of intermediate or high grade were entered onto this study at 17 different centers.
  • Grade 3 or 4 neutropenia occurred in 25% of patients receiving mCHOP and 12% of those receiving full-dose CHOP combined with G-CSF (25% v 12%).
  • There were similar numbers of patients with grade 3 or 4 hyperbilirubinemia (12% and 17%), constipation and abdominal pain (18% and 17%), and transaminase elevation (48% and 52%) on the modified and full-dose arms of the study, respectively.
  • Human immunodeficiency virus (HIV) load declined from a median baseline value of 29,000 copies/mL to a median minimum value on therapy of 500 copies/mL.
  • CONCLUSION: Either modified-dose or full-dose CHOP chemotherapy for HIV-NHL, delivered with HAART, is effective and tolerable.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV Infections / complications. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / virology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Indinavir / administration & dosage. Lamivudine / administration & dosage. Male. Middle Aged. Neutropenia / chemically induced. Prednisone / administration & dosage. Stavudine / administration & dosage. Treatment Outcome. Vincristine / administration & dosage. Viral Load

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Non-ARV Adverse Events .
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • Hazardous Substances Data Bank. INDINAVIR SULFATE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. STAVUDINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11304769.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA 70054; United States / NCI NIH HHS / CA / U01 CA 70072; United States / NCI NIH HHS / CA / U01 CA70019; United States / NCI NIH HHS / CA / U01 CA70047; United States / NCI NIH HHS / CA / U01 CA70058; United States / NCI NIH HHS / CA / U01 CA70062; United States / NCI NIH HHS / CA / U01 CA7007; United States / NCI NIH HHS / CA / U01 CA70078; United States / NCI NIH HHS / CA / U01 CA70080; United States / NCI NIH HHS / CA / U01 CA70081; United States / NCI NIH HHS / CA / U01 CA71375
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 2T8Q726O95 / Lamivudine; 5J49Q6B70F / Vincristine; 5W6YA9PKKH / Indinavir; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BO9LE4QFZF / Stavudine; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


15. Pectasides D, Economopoulos T, Kouvatseas G, Antoniou A, Zoumbos Z, Aravantinos G, Tsatalas C, Halikia A, Nikolaides C, Kiamouris C, Pappa E, Pavlidis N, Skarlos D, Fountzilas G, Dimopoulos MA: Anthracycline-based chemotherapy of primary non-Hodgkin's lymphoma of the testis: the hellenic cooperative oncology group experience. Oncology; 2000 May;58(4):286-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anthracycline-based chemotherapy of primary non-Hodgkin's lymphoma of the testis: the hellenic cooperative oncology group experience.
  • Testicular non-Hodgkin's lymphoma is an uncommon disease and its outcome following chemotherapy and/or radiotherapy has been variable.
  • A retrospective analysis was performed on 26 patients with primary testicular lymphoma treated predominantly with anthracycline-based chemotherapy between 1984 and 1999.
  • There were 11 (42.3%) patients with high grade lymphoma, 12 (46.2%) with intermediate grade, 1 (3.8%) with low grade and 2 (7.7%) were not classified.
  • Chemotherapy was administered to 24 patients including 22 patients who received anthracycline-based chemotherapy.
  • Two stage IEA patients were treated with orchidectomy and adjuvant radiotherapy to the regional lymph nodes without systemic chemotherapy.
  • Chemotherapy alone resulted in a complete remission (CR) in 14 (58.3%) of 24 patients and partial remission in 1 (4.2%), amounting to an overall response rate (RR) of 62.5%.
  • Of the 5 stage I patients who had chemotherapy on an adjuvant basis, 4 (80%) had CR/no evidence of disease.
  • Excluding the 5 stage I patients, chemotherapy resulted in a CR in 10/19 (52.6%) patients and a PR in 1/19 (5.2%), inducing an overall RR of 57.8%.
  • After a median follow-up of 87 months (range 0.13-145.5+ months) the median survival time was 31 months (range 0.13-145.5+ months) and the median time to progression (TTP) 17 months (range 0.13-145.5+ months).
  • The other 2 patients who relapsed did not respond to salvage chemotherapy and died.
  • In conclusion, patients with primary testicular lymphoma have a poor outcome, despite the treatment with anthracycline-containing regimens.
  • Treatment with anthracycline-based chemotherapy is recommended in patients at early stages.
  • Because the relapse rate in the CNS and contralateral testis is quite high in most studies, prophylactic CNS treatment and radiotherapy to the other testis should be included in the management of testicular lymphoma.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10838493.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic
  •  go-up   go-down


16. Ohga S, Nakamura K, Shioyama Y, Sasaki T, Urashima Y, Terashima H, Honda H: Stage I and II non-Hodgkin's lymphoma: results of combined of THP-COP chemotherapy and radiotherapy. Radiat Med; 2005 May;23(3):156-61
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I and II non-Hodgkin's lymphoma: results of combined of THP-COP chemotherapy and radiotherapy.
  • PURPOSE: We evaluated the usefulness of radiotherapy plus THP-COP chemotherapy consisting of cyclophosphamide, vincristine, pirarubicin (tetrahydropyranyl adriamycin, THP), and prednisone for stage I and II non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: Between October 1998 and October 2001, 32 patients with Stage I or II NHL were treated with THP-COP plus radiotherapy.
  • The histological type was intermediate grade in 29, high in one, and unclassified in two.
  • Doses of irradiation ranged from 18.0 to 46.5 Gy (median, 40.0 Gy).
  • Leukopenia of grade 3-4 was documented in 24 patients (75%) and thrombopenia of grade 3-4 in four (12.5%).
  • CONCLUSION: THP-COP plus radiotherapy appeared to be feasible for stage I and II NHL patients.
  • However, further evaluation is needed to determine the usefulness of this treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15940061.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


17. Akutsu M, Tsunoda S, Izumi T, Tanaka M, Katano S, Inoue K, Igarashi S, Hirabayashi K, Furukawa Y, Ohmine K, Sato K, Kobayashi H, Ozawa K, Kirito K, Nagashima T, Teramukai S, Fukushima M, Kano Y: Long-term results of dose-intensive chemotherapy with G-CSF support (TCC-NHL-91) for advanced intermediate-grade non-Hodgkin's lymphoma: a review of 59 consecutive cases treated at a single institute. Oncol Res; 2008;17(3):137-49
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of dose-intensive chemotherapy with G-CSF support (TCC-NHL-91) for advanced intermediate-grade non-Hodgkin's lymphoma: a review of 59 consecutive cases treated at a single institute.
  • We evaluated the long-term outcome of very dose-intensive chemotherapy (TCC-NHL-91) for advanced intermediate-grade lymphoma, in which an eight-cycle regimen with 11 drugs was given with granulocyte colony-stimulating factor (G-CSF) support (total 18 weeks).
  • Forty-three patients (73%) were in a high-intermediate risk or high-risk group (HI/H) according to the age-adjusted International Prognostic Index (aa-IPI).
  • Forty-six patients received 7 or 8 cycles of therapy.
  • Grade 4 hematotoxicity was observed in all patients.
  • One patient died of sepsis during the therapy and one died of secondary leukemia.
  • This retrospective study suggests that the TCC-NHL-91 regimen achieves high CR, OS, and PFS in patients with advanced intermediate-grade lymphoma up to 60 years old and may be a valuable asset in the management of this disease.
  • Further evaluation and prospective studies of the TCC-NHL-91 are warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prednisone / administration & dosage. Remission Induction. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18669165.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


18. Bower M, Stern S, Fife K, Nelson M, Gazzard BG: Weekly alternating combination chemotherapy for good prognosis AIDS-related lymphoma. Eur J Cancer; 2000 Feb;36(3):363-7
Genetic Alliance. consumer health - AIDS-HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly alternating combination chemotherapy for good prognosis AIDS-related lymphoma.
  • Early studies reported that the major adverse prognostic factors in AIDS-related non-Hodgkin's lymphoma (ARL) are low CD4 cell count, prior AIDS defining diagnosis and poor performance status.
  • These patients with one or no adverse prognostic factors were treated with alternating weekly chemotherapy using the bleomycin, etoposide, vincristine, methotrexate, prednisolone/cyclophosphamide, doxorubicin (BEMOP/CA) schedule (Bower M, Block C, Gulliford T, et al.
  • The International non-Hodgkin's lymphoma (NHL) prognostic factors project classifications were low risk 8 (maximum 5.4 years) (27%), low-intermediate risk 6 (20%), high-intermediate risk 11 (37%) and high risk 5 (17%).
  • 3 patients withdrew from treatment within 2 weeks due to toxicity, 2 patients died within 2 weeks of starting chemotherapy.
  • The major toxicity was myelosuppression with 14 patients developing grade 4 neutropenia.
  • The 2-year overall survival rate is 46% (95% confidence interval (CI)=27-65%), and lymphoma-specific survival at 2 years is 59% (95% CI: 40-78%).
  • For selected patients with good prognosis ARL 12 weeks BEMOP/CA therapy produces good overall survival at 2 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neutropenia / chemically induced. Prognosis. Recurrence. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10708938.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


19. Economopoulos T, Dimopoulos MA, Mellou S, Pavlidis N, Samantas E, Nicolaides C, Tsatalas C, Papadopoulos A, Papageogriou E, Papasavvas P, Fountzilas G: Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP. Eur J Haematol; 2002 Mar;68(3):135-43
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
  • INTRODUCTION: During the last few years epirubicin (E) and mitoxantrone (M) (Novantrone) have been used in the treatment of non-Hodgkin's lymphoma (NHL), because of their favorable principal profile.
  • In particular, M has less severe non-hematological toxicity.
  • PATIENTS AND METHODS: A randomized multicenter phase III study was conducted in order to compare the efficacy and toxicity of CEOP and CNOP in intermediate- and high-grade NHL.
  • With a median follow-up time of 47.3 months, the median survival was not reached in arm A, while it was 39.5 months in arm B (P=0.09).
  • There was no significant difference regarding the time to progression between the two groups (29.7 vs. 18.5 months); furthermore the median duration of CRs was 71.6 and 49 months for CEOP and CNOP, respectively (P=0.07).
  • The therapeutic efficacies of both regimens were equivalent among the four IPI groups.
  • WHO grade >2 neutropenia was more frequent in arm B.
  • Supportive treatment with G-CSF was given to 22 and 24 patients, respectively.
  • CONCLUSION: There were no significant differences in terms of overall response rates, overall survival and time to progression between CEOP and CNOP in the treatment of intermediate- and high-grade NHL.
  • Patients with low or low intermediate IPI risk treated with either CEOP or CNOP showed significantly better survival, response rates and time to progression than those with high intermediate or high IPI risk.
  • Therefore, new improved therapeutic approaches should be developed for the treatment of high IPI risk patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Epirubicin / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Mitoxantrone / therapeutic use. Prednisolone / therapeutic use. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Alopecia / chemically induced. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Middle Aged. Neutropenia / chemically induced. Remission Induction. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Steroids.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12068793.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Denmark
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; CEOP protocol 1; MCOP protocol
  •  go-up   go-down


20. Hosing C, Saliba RM, Körbling M, Acholonu S, McMannis J, Anderlini P, Giralt S, De Lima M, Okoroji GJ, Couriel DR, Champlin R, Khouri IF, Donato ML: High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Jul;47(7):1290-4
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma.
  • Rituximab, an anti-CD20 human-mouse chimeric monoclonal antibody has been shown to improve response rates when it is combined with standard salvage chemotherapy in patients with relapsed or refractory intermediate-grade B-cell non-Hodgkin's lymphoma.
  • A vast majority of these patients subsequently undergo high-dose therapy followed by stem cell transplantation.
  • The purpose of this study was to study the effect of high-dose rituximab given with chemotherapy on stem cell mobilization in patients with intermediate-grade B-cell non-Hodgkin's lymphoma.
  • The chemotherapy regimen was well tolerated.
  • All patients who subsequently underwent high-dose chemotherapy and stem cell transplantation experienced sustained engraftment.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Mobilization / methods. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / therapy. Stem Cells / drug effects
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / biosynthesis. Antigens, CD34 / biosynthesis. Etoposide / administration & dosage. Female. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Ifosfamide / administration & dosage. Immunologic Factors / administration & dosage. Kinetics. Male. Middle Aged. Recombinant Proteins. Rituximab. Stem Cell Transplantation / methods

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923559.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antigens, CD34; 0 / Antineoplastic Agents; 0 / Immunologic Factors; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; PVI5M0M1GW / Filgrastim; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


21. Chrischilles EA, Link BK, Scott SD, Delgado DJ, Fridman M: Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma. Cancer Control; 2003 Sep-Oct;10(5):396-403
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma.
  • BACKGROUND: Six to eight cycles of CHOP therapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) is standard for intermediate-grade non-Hodgkin's lymphoma (NHL) but is associated with toxicity that may cause premature termination of therapy.
  • METHODS: We studied factors associated with premature termination of CHOP therapy (receiving fewer than 6 cycles) and the relationship of premature termination with survival.
  • Subjects consisted of a population-based sample of Iowa residents with intermediate-grade NHL who were planned to receive > or = 6 or more cycles of CHOP and who were chemosensitive (ie, achieved a documented partial or complete response to CHOP).
  • RESULTS: In a comparison with patients 18-59 years of age, the odds of premature termination of CHOP therapy was 2.6 (95% CI, 0.7-9.2) for those aged 60-74 and 6.2 (95% CI, 1.7-23.3) for those aged > or = 75.
  • Patients with cycle 1 febrile neutropenia hospitalization (FNH) were 4.4 times (95% CI, 1.4-13.8) more likely to terminate CHOP prematurely than those without cycle 1 FNH.
  • Among patients aged 60-74, but not those aged > or = 75, premature termination appeared to be associated with decreased 5-year survival (hazard ratio [HR] = 6.0; 95% CI, 2.4-15.2) compared with those completing CHOP therapy (HR = 2.1; 95% CI, 1.0-4.2).
  • CONCLUSIONS: First-cycle FNH and age > or = 60 years were associated with premature termination of CHOP therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / adverse effects. Retrospective Studies. Risk Factors. Survival Rate. Vincristine / administration & dosage. Vincristine / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14581895.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


22. Nademanee A, Molina A, Dagis A, Snyder DS, O'Donnell MR, Parker P, Stein A, Smith E, Planas I, Kashyap A, Spielberger R, Fung H, Krishnan A, Bhatia R, Wong KK, Somlo G, Margolin K, Chow W, Sniecinski I, Vora N, Slovak M, Niland JC, Forman SJ: Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma. Clin Lymphoma; 2000 Jun;1(1):46-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
  • The primary objective of this study was to evaluate the outcome of patients treated with high-dose chemo-/radiotherapy or high-dose chemotherapy and autologous stem-cell transplant (ASCT) for relapsed, refractory, or poor-risk intermediate-grade (IG) and high-grade (HG) non-Hodgkin's lymphoma (NHL).
  • Between February 1987 and August 1998, 264 patients, 169 (64%) IG and 95 (36%) HG, underwent high-dose therapy and ASCT at City of Hope National Medical Center (COHNMC).
  • The median number of prior chemotherapy regimens was 2 (range, 1-4), and 71 (27%) had received prior radiation as part of induction or as salvage therapy.
  • The median time from diagnosis to ASCT was 10.8 months (range, 3-158 months).
  • There were 27 deaths (10%) from nonrelapse mortality, including seven (3%) patients who developed second malignancies (five with myelodysplasia/acute myelogenous leukemia and two with solid tumors).
  • Our results further support the role of high-dose therapy and ASCT during first CR/PR for patients with poor-risk intermediate- and high-grade NHL.
  • Early transplant is recommended for patients failing initial induction therapy or relapsing after chemotherapy-induced remission.
  • Relapse continues to be the most common cause of treatment failure.
  • The development of a second malignancy is a serious complication of high-dose therapy, which requires close surveillance.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Risk Factors. Survival Rate. Transplantation, Autologous. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707813.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P0CA30206; United States / NCI NIH HHS / CA / P0CA33572
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


23. Stein RS, Greer JP, Goodman S, Brandt SJ, Morgan D, Macon WR, McCurley TL, Wolff SN: Intensified preparative regimens and allogeneic transplantation in refractory or relapsed intermediate and high grade non-Hodgkin's lymphoma. Leuk Lymphoma; 2001 Apr;41(3-4):343-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensified preparative regimens and allogeneic transplantation in refractory or relapsed intermediate and high grade non-Hodgkin's lymphoma.
  • Between September 1986 and June 1998, 32 patients with relapsed or refractory intermediate or high grade lymphoma received intensified preparative therapy and underwent allogeneic transplantation at a single institution.
  • Patients were considered for allogeneic transplantation if they failed to respond to initial therapy, failed to respond to salvage therapy, relapsed after autologous transplantation, had bone marrow involvement, or failed attempts to harvest autologous stem cells.
  • Patients had a median age of 39 years and had generally received at least two chemotherapy regimens.
  • Survival was significantly worse in patients who had received high intensity brief duration chemotherapy prior to transplantation and was also significantly worse in patients who did not receive total body irradiation (TBI).
  • While treatment related mortality played a major role in limiting the effectiveness of allogeneic transplantation, in this heavily pre-treated population of patients with resistant disease, only 39% of patients achieved a complete response following allogeneic transplantation, and in only 40% of that group was long term disease free survival achieved.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Non-Hodgkin / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Actuarial Analysis. Adolescent. Adult. Child. Disease-Free Survival. Female. Humans. Male. Middle Aged. Recurrence. Retrospective Studies. Survival Rate. Transplantation, Homologous / methods. Transplantation, Homologous / mortality. Transplantation, Homologous / standards. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11378547.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


24. Krol AD, Berenschot HW, Doekharan D, Henzen-Logmans S, van der Holt B, van 't Veer MB: Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy. Radiother Oncol; 2001 Mar;58(3):251-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy.
  • BACKGROUND: A limited number cycles of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy followed by involved field radiotherapy is the treatment of choice for Ann Arbor stage I intermediate or high grade non-Hodgkin's lymphomas (NHL).
  • In this retrospective single-center study we evaluated the results of a combined modality treatment strategy that adapts the radiotherapy dose to the response after chemotherapy, and focus on the influence of radiotherapy dose on local control and survival.
  • PATIENTS AND METHODS: One hundred and forty patients with NHL Ann Arbor stages I/IE of intermediate or high grade malignancy received four cycles of CHOP chemotherapy followed by involved field radiotherapy (IF-RT).
  • The radiotherapy dose for patients in complete response (CR) after CHOP was either 26 or 40 Gy.
  • Patients in partial response (PR) after CHOP always received 40 Gy.
  • The influence of the radiotherapy dose on treatment outcome was evaluated for patients in CR at the end of treatment (n=128).
  • RESULTS: CR rates after chemotherapy and after radiotherapy were 67 and 91%, respectively.
  • Seventy-four of the patients in CR after CHOP received 26 Gy, 20 patients in CR after CHOP 40 Gy.
  • All patients in PR after CHOP (n=34) received 40 Gy.
  • The localization of relapse (within or outside the radiation field) did not differ between patients receiving 26 or 40 Gy.
  • Overall survival (OS) at 5 years for patients in CR after CHOP who received 26 and 40 Gy and for patients in PR after CHOP but CR after 40 Gy IF-RT was 76, 100 and 75%, respectively, (P=0.16), disease free survival (DFS) at 5 years 69, 90 and 75%, respectively, (P=0.52).
  • CONCLUSIONS: No statistically significant differences in patterns of relapse or survival were found between patients receiving 26 or 40 Gy IF-RT, however the number of events in all subgroups was small.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11230885.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


25. Zhou SY, Shi YK, He XH, Zhang P, Dong M, Huang DZ, Yang JL, Zhang CG, Liu P, Yang S, Feng FY: [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma]. Ai Zheng; 2005 Apr;24(4):465-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: So far, there is still no standard salvage regimen for relapsed or refractory non-Hodgkin's lymphoma (NHL).
  • The response rates (RR) of NHL patients received common salvage regimens, such as DICE, ESHAP, MINE, and EPOCH, are only 30%-70%.
  • This study was to evaluate the efficacy and safety of DICE regimen, as a salvage regimen, in treating patients with relapsed or refractory intermediate and high grade NHL.
  • METHODS: Thirty-five patients with relapsed or refractory intermediate and high grade NHL, who had been pretreated with chemotherapy dominated by CHOP or CHOP-like regimen with a median of 6 cycles (ranged 2-12 cycles), were salvaged by DICE regimen from Jun.
  • The total RR was 74.3% with complete response (CR) rate of 31.4%, median response time (MST) of 4 months (ranged 1-30 months), median time to failure (TTF) of 7 months (ranged 2-34 months),median survival time (MST) of 14 months (ranged 3-51 months), and 2-year survival rate of 33.3%.
  • The RRs of T-cell and B-cell NHL were 85.7% and 66.7%.
  • The CR rate was higher in T-cells NHL than in B-cell NHL (50.0% vs. 19.0%, P=0.073).
  • The response to DICE reginmen was an independent prognostic factor of patients with relapsed or refractory NHL (P = 0.001).
  • Incidences of neutropenia and thrombocytopenia of grade III-IV were 71.4% and 8.6%.
  • CONCLUSIONS: DICE regimen is a safe and effective salvage regimen for the patients with relapsed or refractory intermediate and high grade advanced NHL.
  • The response to DICE regimen may directly influence survival time of patients with relapsed or refractory NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Salvage Therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cisplatin / administration & dosage. Cisplatin / adverse effects. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Drug Administration Schedule. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Neoplasm Recurrence, Local. Neutropenia / chemically induced. Remission Induction. Survival Rate. Thrombocytopenia / chemically induced. Transplantation, Autologous

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820071.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; EC 1.1.1.27 / L-Lactate Dehydrogenase; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; DICE protocol
  •  go-up   go-down


26. Tulpule A, Espina BM, Pedro Santabarbara AB, Palmer M, Schiflett J, Boswell W, Smith S, Levine AM: Treatment of AIDS related non-Hodgkin's lymphoma with combination mitoguazone dihydrochloride and low dose CHOP chemotherapy: results of a phase II study. Invest New Drugs; 2004 Jan;22(1):63-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of AIDS related non-Hodgkin's lymphoma with combination mitoguazone dihydrochloride and low dose CHOP chemotherapy: results of a phase II study.
  • PURPOSE: To evaluate the response and side effects of combination therapy with low dose CHOP chemotherapy and mitoguazone dihydrochloride in patients with non-Hodgkin's lymphoma associated with the acquired immunodeficiency syndrome (AIDS-NHL).
  • METHODS: Eighteen patients newly diagnosed with intermediate or high-grade AIDS-NHL were treated with low dose CHOP as follows: day 1, cyclophosphamide 350 mg/m(2), intravenously (IV); doxorubicin 25mg/m(2) IV; vincristine 2mg IV; and prednisone 100mg given orally on days 1 through 5.
  • In addition, mitoguazone dihydrochloride was given at a dose of 600 mg/m(2) IV on days 1 and 15 of each 28-day treatment cycle.
  • Twelve patients had high-grade pathologies while the remainder had an intermediate grade pathology (diffuse large cell).
  • Three patients (17%) reported an AIDS-defining illness prior to lymphoma diagnosis.
  • The median failure free and overall survival times were 6.5 and 8.4 months, respectively.
  • Major toxicity was hematologic with grade 3 or 4 neutropenia in 72%; two patients died of neutropenic sepsis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Mitoguazone / administration & dosage. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1991 Dec 1;68(11):2466-72 [1933784.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1094-103 [9060550.001]
  • [Cites] Invest New Drugs. 1996;14(2):227-34 [8913846.001]
  • [Cites] J Clin Oncol. 1983 Jan;1(1):52-65 [6230418.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] Blood. 1992 Jul 1;80(1):8-20 [1319239.001]
  • [Cites] Ann Intern Med. 1990 Aug 15;113(4):276-82 [1973886.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):3026-35 [8918501.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] J Clin Oncol. 1987 Sep;5(9):1322-8 [2442321.001]
  • [Cites] Am J Med. 1993 Aug;95(2):188-96 [7689296.001]
  • [Cites] JAMA. 1991 Jul 3;266(1):84-8 [1710673.001]
  • [Cites] Ann Intern Med. 1985 Sep;103(3):402-3 [2992336.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Invest New Drugs. 1992 Nov;10(4):239-53 [1487397.001]
  • (PMID = 14707495.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; OD5Q0L447W / Mitoguazone; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


27. Yuan ZY, Xu RH, He YJ, Guan ZZ: [Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma]. Ai Zheng; 2003 Apr;22(4):393-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: The side effects of glucocorticoid, for example inducing or sharpening diabetes, should be considered in treatment of non-Hodgkin's lymphoma (NHL) accompanied by diabetes mellitus with CHOP regimen[Adriamycin(doxorubicin)+cyclophosphamide+Oncovin(Vincristine)+prednisone].
  • METHODS: From June 1991 to May 1999, 53 patients with histologically and immunohistochemically proven of intermediate-grade NHL accompanied by diabetes mellitus were analyzed retrospectively.
  • CONCLUSION: CHO regimen may be selected in treatment of intermediate-grade NHL accompanied by diabetes mellitus.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12703996.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CAV protocol; CHOP protocol
  •  go-up   go-down


28. Chisesi T, Polistena P, Contu A, Coser P, Indrizzi L, Leoni P, Majolino I, Porcellini A, Salvagno L, Zambaldi G, Rizzoli V, Congiu AM, Santini G, Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG): Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patients. Leuk Lymphoma; 2001 Mar;41(1-2):125-36
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patients.
  • Here we report the results of a randomised multicenter phase III clinical trial which assesses the therapeutic efficacy and tolerability of a chemotherapy protocol CEMP (cyclophosphamide, etoposide, mitoxantrone and prednisone) in adult and elderly patients with advanced intermediate and high-grade NHL.
  • Between October 1991 and October 1995, 139 patients, aged 55 to 79 years, with diffuse intermediate and high-grade lymphoma, were enrolled.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Actuarial Analysis. Age Factors. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / standards. Cyclophosphamide / toxicity. Disease-Free Survival. Etoposide / administration & dosage. Etoposide / standards. Etoposide / toxicity. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / standards. Mitoxantrone / toxicity. Prednisone / administration & dosage. Prednisone / standards. Prednisone / toxicity. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11342364.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; CEMP protocol
  •  go-up   go-down


29. De Paoli P, Vaccher E, Tedeschi R, Caffau C, Zanussi S, Bortolin MT, Crepaldi C, Spina M, Tirelli U: Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotherapy. Cancer Immunol Immunother; 2001 May;50(3):157-62
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotherapy.
  • The anti-CD20 monoclonal antibody Rituximab is a novel antitumor agent used in association with chemotherapy (CT) for the treatment of high-grade/intermediate non-Hodgkin's lymphomas (NHL) in HIV-negative populations.
  • This therapeutic combination is currently also being explored in HIV-positive patients with NHL (HIV-NHL).
  • The objective of our study was to determine CD4 and CD8T cell counts, HIV plasma viremia and proviral load in patients with CD20-positive HIV-NHL treated with Rituximab plus CT and highly active antiretroviral therapy (HAART).
  • We studied eight patients with HIV-NHL treated by anti-CD20 and CT before, after three, and after six cycles of therapy; CD4, CD8 and CD19 lymphocyte subsets were measured by monoclonal antibodies and flow cytometry.
  • CD4T cell counts remained stable after three cycles of therapy, while a significant reduction of this subset was present at the end of therapy.
  • HIV plasma viremia was significantly reduced after the third cycle, but returned to pretreatment levels at the end of therapy; we also observed individual fluctuations of proviral load during therapy, this marker being increased in two out of three patients at the end of therapy.
  • These observations suggest that Rituximab plus CT accelerated the rate of CD4 depletion and of HIV replication in the peripheral blood of HIV-NHL patients and that HAART may be able to delay these effects.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / immunology. Antineoplastic Agents / therapeutic use. HIV Seropositivity / immunology. Lymphocyte Subsets / metabolism. Lymphocyte Subsets / virology. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / therapy. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antigens, CD19 / biosynthesis. CD4-Positive T-Lymphocytes / metabolism. CD8-Positive T-Lymphocytes / metabolism. Female. Flow Cytometry. HIV / metabolism. Humans. Leukocytes, Mononuclear / virology. Male. Middle Aged. RNA, Messenger / metabolism. Rituximab. Time Factors

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11419183.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD19; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / RNA, Messenger; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


30. Li YH, Jiang WQ, Huang HQ, Xu RH, Lin TY, Xia ZJ, He YJ, Guan ZZ: [Clinical analysis of 75 patients with nasopharyngeal non-Hodgkin's lymphoma]. Ai Zheng; 2003 Apr;22(4):401-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 75 patients with nasopharyngeal non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: Nasopharynx is one of the common extranodal involved site in non-Hodgkin's lymphoma.However,no standard treatment regimen ever established for nasopharyngeal lymphoma(NPL).
  • The purpose of this paper is to investigate the clinical characteristics and treatment results of NPL.
  • METHODS: The authors reviewed the records of 75 NPL patients who were managed from June 1976 to August 2001 in Cancer Center,Sun Yat-sen University,to evaluate the influence of clinical characteristics and treatment modality on survival.
  • The most common pathological type was intermediate grade(95.2%) and the most common immune phenotype was B-cell lineage (68.6%).
  • These patients were treated with chemotherapy plus radiotherapy (64%),chemotherapy alone (23%),and radiotherapy alone (14%),respectively.
  • For the patients who treated with stranded CHOP (cyclophosphamide + hydroxydaunomycin + Oncovin + prednisone) chemotherapy regimen.
  • There was also no difference in the survival between radiotherapy dosage <or=50 Gy and >50 Gy.
  • CONCLUSION: The treatment modality for NPL should include systemic chemotherapy with CHOP regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Nose Neoplasms / drug therapy. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12703998.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


31. He YF, Li YH, Huang HQ, Xia ZJ, Sun XF, Lin TY, Lin XB, Yuan ZY, Li ZM, Wang FH, Wang SS, Jiang WQ: [Clinical analysis of 59 cases of primary gastric non-Hodgkin's lymphoma]. Ai Zheng; 2005 Apr;24(4):475-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 59 cases of primary gastric non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: Gastrointestinal tract is the most common extranodal involvement site of non-Hodgkin's lymphoma (NHL).
  • However, no standard treatment regimen has ever been established for primary gastric NHL (PGNHL).
  • This paper was to summarize the clinical characteristics and treatment results of PGNHL patients.
  • 2002 in Cancer Center of Sun Yat-sen University, were reviewed to summarize their clinical characteristics, and influence of treatment modality on their survival.
  • According to Working Formulation, most of them were in intermediate grade (46, 78.0%).
  • These patients were treated with chemotherapy plus surgery (37,62.7%), chemotherapy alone (17,28.8%), and surgery alone (5,8.5%), respectively.
  • For those patients in intermediate grade (including immunoblastic cell lymphoma), there was no significant difference in the 5-year survival rate between the patients received chemotherapy plus surgery and the patients received chemotherapy alone (52.5% vs. 57.1%).
  • CONCLUSIONS: Chemotherapy-dominated modality is recommended for patients with PGNHL of intermediate or high grade.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820073.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


32. Chen SP, Wu DS, Zhao XL: [Clinical analysis of 282 patients with non-Hodgkin's lymphoma]. Hunan Yi Ke Da Xue Xue Bao; 2003 Jun;28(3):237-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 282 patients with non-Hodgkin's lymphoma].
  • OBJECTIVE: To analyze the classification, stage and prognosis of non-Hodgkin's lymphoma (NHL).
  • METHODS: Two hundred eighty two patients with NHL were retrospectively reviewed.
  • RESULTS: The complete remission (CR) rate and 5-year survival rate of B-cell NHL were higher than those of T-cell NHL(P < 0.05).
  • There were significant differences in CR rate and 5-year survival rate among the low-grade, the intermediate-grade and the high-grade NHL(P < 0.05).
  • CONCLUSION: Rational classification and staging play an important role in the prognosis of NHL.
  • CHOP-based scheme may be regarded as the first choice and the standard scheme of treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Infant. Male. Middle Aged. Prednisone / administration & dosage. Prognosis. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14653077.001).
  • [ISSN] 1000-5625
  • [Journal-full-title] Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University
  • [ISO-abbreviation] Hunan Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


33. Sieber M, Tesch H, Pfistner B, Rueffer U, Lathan B, Brosteanu O, Paulus U, Koch T, Pfreundschuh M, Loeffler M, Engert A, Josting A, Wolf J, Hasenclever D, Franklin J, Duehmke E, Georgii A, Schalk KP, Kirchner H, Doelken G, Munker R, Koch P, Herrmann R, Greil R, Anselmo AP, Diehl V: Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol; 2002 Jan 15;20(2):476-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
  • PURPOSE: To investigate whether treatment results in intermediate-stage Hodgkin's lymphoma can be improved by rapid application of non-cross-resistant drugs, the 10-drug regimen cyclophosphamide, vincristine, procarbazine, and prednisone (COPP), doxorubicin, bleomycin, and vinblastine (ABV), and ifosfamide, methotrexate, etoposide, and prednisone (IMEP), repeated every 6 weeks, was compared with conventional alternating COPP/doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) administered every 8 weeks.
  • PATIENTS AND METHODS: From January 1988 to January 1993, 996 patients in stage I or II Hodgkin's lymphoma with at least one risk factor (massive mediastinal tumor, massive spleen involvement, extranodal disease, elevated ESR, or more than two lymph node areas involved) and all patients in stage IIIA Hodgkin's lymphoma were randomized to receive two cycles of COPP/ABVD or COPP/ABV/IMEP followed by extended-field radiotherapy.
  • RESULTS: Both regimens produced similar rates for treatment responses (complete remission, 93% v 94%), freedom from treatment failure (80% v 79%), and overall survival (88% for both regimens) at a median follow-up time of 7 years.
  • Most serious toxicities during chemotherapy were similar in both regimens.
  • However, World Health Organization grade 3 and 4 leukocytopenia occurred significantly more frequently in the COPP/ABV/IMEP arm (53% v 44% of patients; P =.010).
  • There were no differences in the number of serious infections and toxic deaths during therapy.
  • CONCLUSION: Alternating COPP/ABVD and rapid alternating COPP/ABV/IMEP in combination with extended-field radiotherapy are equally effective in intermediate-stage Hodgkin's lymphoma and produce excellent long-term treatment results.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Prednisone / administration & dosage. Procarbazine / administration & dosage. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11786577.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ABVD protocol; COPP protocol; VBA protocol
  •  go-up   go-down


34. Straus DJ: Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma. Recent Results Cancer Res; 2002;159:143-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma.
  • Chemotherapy regimens similar to those used for non-Hodgkin's lymphoma (NHL) not associated with human immunodeficiency virus (HIV) infection have been used for patients with HIV-associated NHL with less success.
  • In a recent trial, patients with intermediate or high-grade NHL were randomized to either low-dose chemotherapy with methotrexate, bleomycin, doxorubicin, vincristine and dexamethasone (m-BACOD) or to standard-dose m-BACOD with sargramostim (granulocyte-macrophage colony-stimulating factor, GM-CSF).
  • Myelosuppression was greater with standard-dose chemotherapy.
  • In univariate and multivariate analyses of 21 pretreatment features of patients in this trial, four factors emerged as adversely prognostic with respect to survival: age >35 years, intravenous drug use, CD4 counts < 100/mm3 and stage III/IV disease.
  • The outcome of these patients may be improving with the use of highly active antiretroviral therapy (HAART), which seems to improve immune function and tolerance of chemotherapy.
  • A recent trial of the AIDS Malignancy Consortium found that low-dose chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone: CHOP) and standard-dose chemotherapy had similar response rates, acceptable toxicity and minimal alterations in cyclophosphamide, doxorubicin and indinavir pharmacokinetics in HIV-associated lymphoma patients also on HAART (stavudine, lamivudine and indinavir).
  • There is a suggestion that Burkitt-type lymphomas may tend to occur in HIV-infected patients with relatively well preserved immune function and CD4 cell counts.
  • Recent results from our institution suggest that similar outcomes are achievable with intensive chemotherapy in patients with Burkitt's lymphomas with or without HIV infection.
  • With improved immune status and improved bone marrow function with the use of HAART, it will probably become more possible to treat many patients with aggressive HIV-associated NHL with more intensive treatment regimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / therapy
  • [MeSH-minor] Adult. Clinical Trials as Topic. Humans. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11785838.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Review
  • [Publication-country] Germany
  • [Number-of-references] 19
  •  go-up   go-down


35. Pfreundschuh M, Zwick C, Zeynalova S, Dührsen U, Pflüger KH, Vrieling T, Mesters R, Mergenthaler HG, Einsele H, Bentz M, Lengfelder E, Trümper L, Rübe C, Schmitz N, Loeffler M, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL): Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol; 2008 Mar;19(3):545-52
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
  • BACKGROUND: The addition of etoposide to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone [etoposide to combination chemotherapy with cyclophosphamide, vincristine and prednisone (CHOEP)] improved outcome of young patients with good-prognosis aggressive lymphoma.
  • PATIENTS AND METHODS: Intention-to-treat analysis of 389 young (18-60 years) patients with good-prognosis (age-adjusted International Prognostic Index = 0, 1) aggressive lymphoma randomized to CHOEP-21 (n = 194) or high CHOEP (n = 195).
  • Neither low-risk nor low-intermediate risk patients benefited from high CHOEP.
  • High CHOEP was more toxic than CHOEP-21 (grades 3 and 4 leukocytopenia 100% versus 87.2%, P < 0.001; thrombocytopenia 80.8% versus 9.6%, P < 0.001; infections 35% versus 11%, P < 0.001; therapy-associated deaths 3.1% versus 0%, P = 0.03).
  • Since differences between chemotherapy regimens are compressed by the addition of rituximab, the results of this trial have bearing on strategies aiming to improve outcome of good-prognosis aggressive lymphomas in the rituximab era.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18065407.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


36. Sunaba K, Shibuya H, Okada N, Amagasa T, Enomoto S, Kishimoto S: Radiotherapy for primary localized (stage I and II) non-Hodgkin's lymphoma of the oral cavity. Int J Radiat Oncol Biol Phys; 2000 Apr 1;47(1):179-83
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy for primary localized (stage I and II) non-Hodgkin's lymphoma of the oral cavity.
  • PURPOSE: To assess the role of radiation therapy in the treatment of primary localized (Stage I: 24 cases and Stage II: 13 cases) non-Hodgkin's Lymphoma (NHL) of the oral cavity.
  • METHODS AND MATERIALS: In total, 37 patients (27 male, 10 female) with primary localized NHL of the oral cavity have been treated with radiotherapy alone (23 cases) or radiation with chemotherapy (14 cases).
  • Clinical and treatment variables with potential prognostic significance for survival were evaluated by univariate and multivariate analysis.
  • Of the 37 patients, 31 (84%) had intermediate-grade lymphomas and six (14%) had high-grade lymphomas.
  • The 5-year survival rates for intermediate-grade and high-grade lymphoma were 85% and 14%, respectively.
  • Significant prognostic factors identified by the multivariate analysis were histologic grade of malignancy (p = 0.02) and central necrotic ulcer in the tumor (p = 0.02).
  • Chemotherapy did not improve survival (p = 0.41).
  • CONCLUSIONS: Our analysis suggests that radiotherapy alone may be approved as the treatment for localized oral NHL with no ulceration and intermediate histology.
  • However, patients with high-grade lymphoma and/or necrotic ulcer are difficult to cure with radiation alone and aggressive treatment should be advocated to improve survival.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy. Mouth Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Combined Modality Therapy. Female. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiotherapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiotherapy. Male. Middle Aged. Neoplasm Staging. Phenotype. Recurrence. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10758321.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


37. Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, Niesvizky R, Shore T, Chadburn A, Horne H, Kovacs J, Ding CL, Wegener WA, Horak ID, Goldenberg DM: Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol; 2005 Aug 1;23(22):5044-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
  • PURPOSE: To explore the safety and therapeutic activity of combination anti-B-cell monoclonal antibody therapy in non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: Twenty-three patients with recurrent B-cell lymphoma received anti-CD22 epratuzumab 360 mg/m(2) and anti-CD20 rituximab 375 mg/m(2) monoclonal antibodies weekly for four doses each.
  • Sixteen patients had indolent histologies (15 with follicular lymphoma) and seven had aggressive NHL (all diffuse large B-cell lymphoma [DLBCL]).
  • Indolent patients had received a median of one (range, one to six) prior treatment, with 31% refractory to their last therapy and 81% with high-risk Follicular Lymphoma International Prognostic Index scores.
  • Patients with DLBCL had a median of three (range, one to eight) prior regimens (14% resistant to last treatment) and 71% had high intermediate-risk or high-risk International Prognostic Index scores.
  • RESULTS: Treatment was well tolerated, with toxicities principally infusion-related and predominantly grade 1 or 2.
  • Ten (67%) patients with follicular NHL achieved an objective response (OR), including nine of 15 (60%) with complete responses (CRs and unconfirmed CRs).
  • Median time to progression for all indolent NHL patients was 17.8 months.
  • CONCLUSION: The full-dose combination of epratuzumab with rituximab was well tolerated and had significant clinical activity in NHL, suggesting that this combination should be tested in comparison with single-agent treatment.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Recurrence. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15955901.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / K23 RR16814
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / epratuzumab; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


38. Zheng W, Yong WB, Zhu J, Zhang YT, Wang XP, Xie Y: [Clinical analysis of liver non-Hodgkin's lymphoma]. Ai Zheng; 2004 Nov;23(11 Suppl):1451-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of liver non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: Incidence of liver non-Hodgkin's lymphoma (NHL) is increasing.
  • This study was to explore clinical features, diagnosis, treatment, and prognosis of liver NHL.
  • METHODS: Records of 45 patients with liver NHL treated in our hospital from Jan.
  • 1998 to May 2002, 9.6% of all NHL patients treated in the same period, were retrospectively analyzed with statistic software package of SPSS10.0.
  • According to International Work Formulation (IWF), 92% of 45 patients belonged to intermediate-grade.
  • Clinical features of liver NHL were presented with fever, jaundice, hepatosplenomegalia, and liver dysfunction.
  • Combination treatment based on chemotherapy was the major therapy.
  • Median survival time was 4 months, overall 1-, and 2-year survival rates were 22%, and 18%.
  • CONCLUSION: Early diagnose liver NHL is difficult, its treatment effect and prognosis are poor, combination therapy should be given as early as possible.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Alanine Transaminase / blood. Aspartate Aminotransferases / blood. Bilirubin / blood. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Lymphoma, B-Cell / blood. Lymphoma, B-Cell / drug therapy. Lymphoma, T-Cell / blood. Lymphoma, T-Cell / drug therapy. Male. Middle Aged. Prednisone / administration & dosage. Prognosis. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15566655.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; RFM9X3LJ49 / Bilirubin; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


39. Williams CD, Harrison CN, Lister TA, Norton AJ, Blystad AK, Coiffier B, Taghipour G, Schmitz N, Goldstone AH, European Bone Marrow Transplant Lymphoma Working Party: High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol; 2001 Feb 01;19(3):727-35
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry.
  • PURPOSE: To assess the outcome of high-dose therapy with autologous stem-cell support in patients with histologic transformation of low-grade follicular non-Hodgkin's lymphoma (NHL) and identify significant prognostic factors, as well as to compare survival of these patients with that of patients with matched low-grade and de novo high- or intermediate-grade NHL undergoing the same procedure.
  • PATIENTS AND METHODS: Fifty patients with transformed low-grade NHL have been reported to the European Bone Marrow Transplant registry.
  • Outcome from high-dose therapy and significant prognostic factors were analyzed.
  • Their survival was also compared with that of 200 patients with matched low-grade NHL and 200 patients with matched de novo high- or intermediate-grade NHL by a case-matched analysis.
  • RESULTS: The procedure-related death rate among the 50 transformed NHL patients was 18%.
  • Median PFS time was 13 months.
  • A subgroup of patients with residual chemosensitive disease who attained complete remission after high-dose therapy had the best outcome, with an OS at 5 years of 69%.
  • A comparison with matched patients with low-grade disease and with de novo high- or intermediate-grade lymphoma showed no significant difference in OS (P =.939 and P =.438, respectively).
  • CONCLUSION: Patients with chemosensitive transformed lymphoma should be seriously considered for high-dose therapy and autologous stem-cell support.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Case-Control Studies. Cell Transformation, Neoplastic / pathology. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / pathology. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11157024.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


40. Lorusso V, Palmieri G, Bianco AR, Abate G, Catalano G, De Vita F, Dammacco F, Lauta VM, Lucarelli G, Polimeno G, Mantovani G, D'Aprile M, Marzullo F, De Lena M: CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group. Int J Oncol; 2000 Jan;16(1):149-54
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
  • From January 1992 to December 1995, 129 patients with previously untreated non-Hodgkin's lymphoma were randomised in a phase III multicenter trial to receive CEOP-B/VIMB or ProMACE-CytaBOM.
  • Eligibility criteria included intermediate or high grade lymphoma (follicular large cell, diffuse small cleaved-cell, diffuse mixed, diffuse large-cell and immunoblastic) with an Ann Arbor stage II bulky, III or IV.
  • At a median follow-up of 60 months there were no significant differences between the treatment response rates [82% (60%CR) for CEOP-B/VIMB vs. 81% (69% CR) for ProMACE-CytaBOM].
  • Conversely, with regard to disease-free survival, a significant difference was observed between the two treatment arms (42% for CEOP-B/VIMB vs. 24% for ProMACE-CytaBOM at 5 years; p=0.046).
  • Moreover, when response rates and outcome were analysed for different prognostic subgroups according to International Prognostic Index, no significant differences were observed between the treatment groups.
  • It is important to note that neither regimen was able to improve outcome of poor risk patients who fared badly with both treatments (median survival 9 and 8 months respectively).
  • Toxicity was also similar in both treatments with grade 3-4 leukopenia observed in 39% and 47% of cases and grade 3-4 thrombocytopenia in 24% and 27% of cases respectively.
  • In conclusion, in this study CEOP-B/VIMB was not superior to ProMACE-CytaBOM in aggressive lymphomas and the alternating strategy failed to improve outcome of poor risk patients in which newer more aggressive treatments are needed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Epirubicin / administration & dosage. Epirubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10601560.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CEOP-B protocol; PROMACE-CytaBOM protocol
  •  go-up   go-down


41. Elis A, Tevet A, Yerushalmi R, Blickstein D, Bairy O, Dann EJ, Blumenfeld Z, Abraham A, Manor Y, Shpilberg O, Lishner M: Fertility status among women treated for aggressive non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Apr;47(4):623-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility status among women treated for aggressive non-Hodgkin's lymphoma.
  • In young women treated for intermediate-high-grade non-Hodgkin's lymphoma with CHOP (cyclophosphamide, adriamycin, oncovine and prednisone), there is insufficient data concerning gonadotoxicity or the need for fertility-preserving measures.
  • The aim of the present study was to evaluate the fertility status in the first complete remission of women who were treated for aggressive non-Hodgkin's lymphoma.
  • A cohort of 36 women with aggressive non-Hodgkin's lymphoma in first remission, who were treated in five university-affiliated hospitals in Israel, was evaluated.
  • Menstrual cycle characteristics, as well as pregnancies before the diagnosis, during treatment and in first complete remission, were evaluated.
  • All patients were treated with chemotherapy, although 10 patients received additional radiotherapy.
  • Follow-up time at first complete remission was 84 +/- 48 months.
  • Three patients received gonadtropin-releasing hormone analogs, whereas nine received contraceptive pills together with cytotoxic treatment.
  • During treatment, 18 patients (50%) had amenorrhea, six (17%) had irregular menstrual cycles, and 12 (33%) continued their regular cycles.
  • In 63% of patients, the menstrual cycle recovered within 3 months of the discontinuation of chemotherapy.
  • The two patients who developed amenorrhea were 40 years old at the time of diagnosis.
  • In conclusion, the rate of gonadal dysfunction is very low among young, CHOP treated, non-Hodgkin's lymphoma female patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Fertility. Infertility, Female / etiology. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / pathology. Menstrual Cycle / drug effects
  • [MeSH-minor] Adolescent. Adult. Amenorrhea. Cohort Studies. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Female. Humans. Kinetics. Prednisone / adverse effects. Prednisone / therapeutic use. Remission Induction. Risk. Time Factors. Vincristine / adverse effects. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Female Infertility.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Apr;47(4):574-5 [16886268.001]
  • (PMID = 16690520.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


42. Li YH, Jiang WQ, Huang HQ, Zhang L, Liu DG, Xu RH, Zhou ZM, Sun XF, Lin TY, Xu GC, He YJ, Guang ZZ: [Preliminary study on DHAP regimen for patients with relapsed and refractory non-Hodgkin's lymphoma]. Ai Zheng; 2002 Aug;21(8):900-2
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preliminary study on DHAP regimen for patients with relapsed and refractory non-Hodgkin's lymphoma].
  • BACKGROUND AND OBJECTIVE: The treatment of the patients with relapsed and refractory non-Hodgkin's lymphoma(NHL) remains difficult.
  • It was reported that DHAP regimen(cisplatin + Ara-C + dexamthsone) was an effective salvage therapy, but there was no report about it in China.
  • The current study was designed to observe the efficacy and toxicity of DHAP regimen for the patients with relapsed and refractory NHL.
  • METHOD: Seventeen patients with relapsed and 10 with refractory intermediate or high grade NHL was involved in this study.
  • The effective release time lasted a median of 4.8 months.
  • Median survival time was 8.3 months.
  • Myelosuppression was the major toxicity; 15 patients(57.7%) had grade III-IV neutropenia and 21 patients (80.8%) had grade III-IV thromcytopenia, but there was no treatment-related death.
  • CONCLUSION: The authors conclude that DHAP regimen is an effective salvage therapy for the patients with relapsed and refractory NHL, but the remission duration time is short and long-term prognosis remains poor.
  • High dose chemotherapy supported by APBPCT is necessary for improvement in long-term survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Female. Fever / chemically induced. Humans. Leukopenia / chemically induced. Male. Middle Aged. Nausea / chemically induced. Neoplasm Recurrence, Local. Survival Rate. Treatment Outcome. Vomiting / chemically induced

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12478903.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


43. Crump M, Couban S, Meyer R, Rudinskas L, Zanke B, Gluck S, Maksymiuk A, Hoskins P, Matthews S, Eisenhauer E: Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study. Leuk Lymphoma; 2002 Aug;43(8):1581-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study.
  • Preliminary results indicate that inhibitors of the nuclear enzyme topoisomerase (topo) I, such as topotecan, may be active in non-Hodgkin's lymphoma (NHL).
  • We enrolled, 22 eligible patients with relapsed or refractory intermediate grade NHL in a phase II study ofsequential administration of topotecan 1.25 mg/m2 days 1-5 and etoposide 50 mg po b.i.d. days 6-12, every 28 days without G-CSF.
  • Most patients had diffuse large B-cell lymphoma and all had received only one prior regimen (CHOP, 20 patients, or equivalent, 2 patients).
  • Patients with stable or responding disease were allowed to proceed to high-dose therapy and autologous stem-cell transplant after 2 cycles of therapy.
  • Nineteen of twenty-two patients had grade 3/4 neutropenia, 12 had grade 3/4 thrombocytopenia, and 6 grade 3/4 anemia.
  • Non-hematologic toxicity was mild.
  • The combination of topotecan and etoposide as given in this study has modest activity in relapsed/refractory aggressive histology NHL, and produces marked myelosuppression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Middle Aged. Topotecan / administration & dosage. Topotecan / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12400600.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


44. Salman H, Perez A, Sparano JA, Ratech H, Negassa A, Hopkins U, Villani G, Fuks J, Wiernik PH: Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma. Am J Clin Oncol; 2003 Aug;26(4):338-43
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma.
  • The purpose of this study was to determine the complete response (CR) rate, failure-free survival (FFS), and overall survival (OS) of patients with poor-prognosis intermediate-grade non-Hodgkin's lymphoma (NHL) after treatment with cyclophosphamide, idarubicin, and etoposide given as a continuous intravenous infusion (CIVI) over 96 hours (infusional CIE), including patients with relapsed/refractory disease and patients with no prior therapy but at least two poor-risk features by the age-adjusted International Prognostic Index.
  • Forty-two patients with previously untreated NHL (N = 24) or relapsed/refractory (N = 18) NHL received cyclophosphamide (200 mg/m2/d), idarubicin (2.5-3.0 mg/m2/d) and etoposide (60 mg/m2/d) given by a 96-hour CIVI every 3 weeks for a maximum of 8 cycles.
  • CR occurred in 10 of 24 patients (42%; 95% confidence intervals [CI] 22%, 62%) treated with CIE as first-line therapy, and in 3 of 18 patients (17%; 95% CI 20%, 32%) treated with CIE as second-line or greater therapy.
  • One-year FFS and OS were 42% and 64%, respectively, in patients with no prior therapy, and 17% and 56% in patients with prior therapy.
  • Severe (grade III) or life-threatening (grade IV) toxicity included leukopenia (59%), anemia (61%), thrombocytopenia (31%), and infection (10%).
  • Two patients (4%) died due to treatment related infectious complications.
  • It is unlikely that infusional CIE produces a CR rate more than about 60% in poor-risk patients with intermediate-grade NHL when used as first-line therapy, or more than about 30% in patients receiving the regimen as second-line therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Idarubicin / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Infusions, Intravenous. Male. Middle Aged. Prognosis. Remission Induction. Survival Analysis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12902881.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30-CA113330
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; ZRP63D75JW / Idarubicin
  •  go-up   go-down


45. Tulpule A, Rarick MU, Kolitz J, Bernstein J, Myers A, Buchanan LA, Espina BM, Traynor A, Letzer J, Justice GR, McDonald D, Roberts L, Boswell W, Nathwani B, Levine AM: Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma. Ann Oncol; 2001 Apr;12(4):457-62
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma.
  • PURPOSE: To assess the efficacy and toxicity of liposomal daunorubicin administered as a two-hour intravenous infusion to patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: Eligible patients had relapsed or refractory NHL with measurable or evaluable disease, and low grade, select intermediate grade, or mantle cell pathologic types.
  • RESULTS: Thirty-three patients were accrued: twenty-three (70%) had low-grade histologies; six (18%) had intermediate-grade histologies (follicular large-cell and diffuse small cleaved); and four (12%) patients had mantle-cell lymphoma.
  • The major toxicities were grade 3 or 4 neutropenia in 26 patients (79%), mild to moderate nausea in 22 (67%), and fatigue in 16 (48%).
  • CONCLUSIONS: Liposomal daunorubicin at 100 mg/m2 every three weeks has activity in patients with relapsed or refractory NHL, including patients with prior exposure to an anthracycline.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2001 Apr;12(4):433-4 [11398872.001]
  • (PMID = 11398876.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


46. Montuoro A, Lalle M, Ingletto D: Autologous bone marrow transplantation as consolidation therapy in newly diagnosed non-Hodgkin's lymphoma: long-term outcome. Int J Oncol; 2000 Oct;17(4):771-5
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous bone marrow transplantation as consolidation therapy in newly diagnosed non-Hodgkin's lymphoma: long-term outcome.
  • Autologous bone marrow transplantation (ABMT) often produces durable remission in patients with intermediate-high grade non-Hodgkin's lymphoma (NHL).
  • We present a retrospective review of 32 eligible newly diagnosed patients with NHL treated with conventional induction chemotherapy followed by ABMT consolidation therapy.
  • These patients were treated in our department between 1984-1994 and followed up for 5-172 months with a median time of 82 months.
  • This study confirms that a significant number of patients with aggressive responding NHL can achieve prolonged RFS and OS after ABMT.
  • Our data document the importance of long-term follow-up in interpreting the results of ABMT in NHL.
  • [MeSH-major] Bone Marrow Transplantation. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy / adverse effects. Disease-Free Survival. Female. Humans. Intestinal Mucosa / pathology. Life Support Care. Male. Middle Aged. Mouth Mucosa / pathology. Neoplasm Staging. Neutropenia / etiology. Palliative Care. Retrospective Studies. Stomatitis / etiology. Thrombocytopenia / etiology. Time Factors. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10995890.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GREECE
  •  go-up   go-down


47. Taylor PR, Jackson GH, Galloway MJ, Soukop M, Tinegate H, Angus B, Proctor SJ: Primary treatment of low-grade non-Hodgkin's lymphoma using an all oral anthracycline-containing regimen, chlorambucil, idarubicin, dexamethasone (CID)--a phase II study. Cancer Chemother Pharmacol; 2000;46(1):63-8
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary treatment of low-grade non-Hodgkin's lymphoma using an all oral anthracycline-containing regimen, chlorambucil, idarubicin, dexamethasone (CID)--a phase II study.
  • PURPOSE: The majority of patients with low-grade non-Hodgkin's lymphoma (LGNHL) are in the older age groups and are thus less able to tolerate aggressive treatment.
  • Chlorambucil, alone and in combination, has been widely accepted as the initial treatment of choice for many years.
  • METHODS: Patients (age less than 70 years) with a histologically confirmed diagnosis of LGNHL (Kiel classification) were eligible for the study if they had no previous chemotherapy.
  • Treatment consisted of chlorambucil 20 mg/ m2 daily for 3 days given on each day in three divided doses, idarubicin 10 mg/m2 for 3 days before breakfast, and dexamethasone 4 mg twice daily for 5 days.
  • All drugs were given orally.
  • Treatment was repeated every 21 days for a maximum of six courses.
  • The predominant toxicity was haematological, but in only one course did grade 4 neutropenia (less than 0.5 x 10(9)) occur.
  • Full doses of the treatment were administered to 40% of the patients, with no delays or dose reductions.
  • Six patients had static disease and two progressed on treatment.
  • Lactate dehydrogenase (LDH) was found to be a good predictor of response to treatment.
  • Of 12 patients documented to have raised LDH, 5 failed to respond to treatment, compared to 1 of 32 patients who had a normal LDH (chi2 10.65, P < 0.002).
  • However, in patients with best and intermediate risk LGNHL (by the SNLG Prognostic Index for Low Grade Disease) overall survival are 88% and 64%, respectively.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chlorambucil / therapeutic use. Dexamethasone / therapeutic use. Idarubicin / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Female. Humans. Male. Middle Aged. Outcome Assessment (Health Care). Prognosis

  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10912580.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 18D0SL7309 / Chlorambucil; 7S5I7G3JQL / Dexamethasone; ZRP63D75JW / Idarubicin
  •  go-up   go-down


48. Wang W, Wang L, Huang Y: [Treatment of stage II non-Hodgkin's lymphoma: analysis of 268 patients]. Zhonghua Zhong Liu Za Zhi; 2001 Jul;23(4):335-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of stage II non-Hodgkin's lymphoma: analysis of 268 patients].
  • OBJECTIVE: To seek the optimum treatment for patients with stage II non-Hodgkin's Lymphoma (NHL).
  • METHODS: 268 patients with stage II NHL, treated from January 1987 to December 1993, received radiation alone (R-50), radiation plus chemotherapy (R + C - 73), chemotherapy followed by radiation then by chemotherapy (C + R + C - 72), chemotherapy plus radiation (C + R - 61) or chemotherapy alone (C-12).
  • A total of 206 patients was treated with combined treatment.
  • RESULTS: The 1-, 2-, 3-, 4-, 5- and 6-year survival rates were 95.1%, 87.8%, 87.8%, 85.4%, 82.9%, 53.6% in C + R + C group for patients with stage II high grade NHL, which were much better than those in the R group, R + C group and C + R group (P < 0.01).
  • For patients with stage II intermediate grade NHL, the 1-, 2-, 3-, 4-, 5- and 6-year survival rates were 89.3%, 75.0%, 67.8%, 60.6%, 57.1%, 46.4% in the C + R + C group, which were better than those in the R group, R + C group and C + R group (P > 0.05).
  • However, for patients with low grade NHL, the survival rates were similar both in the R group and the combination groups.
  • CONCLUSION: For patients with stage II intermediate and high grade NHL, combination therapy of C + R + C is recommended.
  • Radiation alone can only be used for patients with stage II low grade NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11783121.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


49. Hoerr AL, Gao F, Hidalgo J, Tiwari D, Blum KA, Mathews V, Adkins DR, Blum W, Devine S, Vij R, Goodnough LT, Dipersio JF, Khoury HJ: Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol; 2004 Nov 15;22(22):4561-6
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma.
  • PURPOSE: To analyze the effects of preautografting treatment with rituximab (R) on stem-cell mobilization, post-transplantation complications, engraftment, disease-free survival, and overall survival in patients with non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: Single-institution retrospective comparative outcome analysis in a cohort of 273 relapsed chemosensitive NHL patients of whom 127 (47%) received R pretransplantation.
  • In contrast to patients with low-grade NHL, both disease-free and overall survival rates were significantly better when R was included in the pretransplantation salvage therapy for patients with intermediate-grade NHL.
  • CONCLUSION: In this large, single-center retrospective analysis, pretransplantation treatment with R was associated with improved survival in patients with intermediate-grade NHL, at the price, however, of a delay in platelet engraftment.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Transplantation Conditioning
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Sep 1;23(25):6261; author reply 6262 [16135496.001]
  • (PMID = 15542807.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


50. Visco C, Medeiros LJ, Mesina OM, Rodriguez MA, Hagemeister FB, McLaughlin P, Romaguera JE, Cabanillas F, Sarris AH: Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy? Clin Lymphoma; 2001 Jun;2(1):40-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy?
  • This study was designed to determine response, outcome, and patterns of failure of patients with non-Hodgkin's lymphoma who presented with a testicular mass.
  • Anderson Cancer Center between 1969 and 1999 treated with doxorubicin-based regimens and with radiotherapy and/or intrathecal therapy were considered for this study.
  • All 43 patients had intermediate-grade lymphomas according to the Working Formulation, and all 31 tumors assessed immunophenotypically were large B-cell lymphoma according to the World Health Organization classification.
  • Thirty-four patients achieved complete remission, 19 of whom relapsed, and 5 failed initial therapy.
  • Doxorubicin-based regimens alone appear unable to cure most patients with lymphoma involving the testis, but CHOP with prophylactic intrathecal therapy and adjuvant scrotal radiotherapy appears promising.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Central Nervous System Neoplasms. Cyclophosphamide / administration & dosage. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prednisone / administration & dosage. Prognosis. Retrospective Studies. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707869.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


51. Lee SC, Wong JE, Kueh YK: Clinical characteristics and treatment outcome of 218 patients with non-Hodgkin's lymphoma in a Singaporean institution. Singapore Med J; 2000 Mar;41(3):118-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and treatment outcome of 218 patients with non-Hodgkin's lymphoma in a Singaporean institution.
  • A retrospective analysis of 218 patients with non-Hodgkin's lymphoma (NHL) seen at a single institution in Singapore over a ten-year period was conducted.
  • Twenty percent, 56% and 24% of patients had low-, intermediate- and high-grade disease respectively using the Working Formulation, and 25% of patients immunophenotyped had T-cell NHL.
  • 86% and 73% respectively of patients with intermediate and high grade disease received combination chemotherapy as first line treatment, with CHOP being the most commonly used regime.
  • Seventy-four percent of patients with low grade lymphoma received first line chemotherapy, 5% each was treated with radiotherapy or surgery alone, and 21% was treated symptomatically.
  • Patients with low grade B-cell lymphoma had a 5-year survival of 80% and 10-year survival of 42%.
  • One-year survival for intermediate and high grade B-cell lymphoma was 76% and 42%, while 2-year survival was 67% and 42% respectively.
  • 1-, 2-, and 3-year survival for patients with T-cell lymphoma was 67%, 46% and 37% respectively.
  • The difference in survival between low-, intermediate- and high-grade B-cell lymphoma was statistically significant (p = 0.0018 using the log rank test), but that between B- and T-cell lymphoma was not.
  • Using the Cox regression model, International prognostic index, grade and extranodal disease were found to be statistically significant predictors of survival (p = 0.0001, p = 0.0157, p = 0.0343) respectively.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged. Retrospective Studies. Singapore. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11063195.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] SINGAPORE
  •  go-up   go-down


52. Chrischilles E, Delgado DJ, Stolshek BS, Lawless G, Fridman M, Carter WB: Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma. Cancer Control; 2002 May-Jun;9(3):203-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma.
  • BACKGROUND: In intermediate-grade non-Hodgkin's lymphoma (NHL) patients, full-dose CHOP improves survival but increases myelosuppression, causing febrile neutropenia hospitalization (FNH) in 28% of patients 65 years of age or greater.
  • Overall, 73% of these hospitalizations occurred within the first 2 cycles of chemotherapy, with 56% occurring within the first cycle.
  • CONCLUSIONS: Older NHL patients have a higher risk of hospitalization for FN and longer LOS.
  • The majority of hospitalization days occur in the first 2 cycles of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colony-Stimulating Factors / therapeutic use. Cyclophosphamide / adverse effects. Doxorubicin / adverse effects. Lymphoma, Non-Hodgkin / drug therapy. Neutropenia / chemically induced. Neutropenia / drug therapy. Prednisone / adverse effects. Vincristine / adverse effects
  • [MeSH-minor] Adult. Age Factors. Aged. Dose-Response Relationship, Drug. Female. Humans. Incidence. Least-Squares Analysis. Length of Stay. Male. Middle Aged. Multivariate Analysis. Recurrence. Retrospective Studies. Risk Factors. Statistics, Nonparametric. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12060818.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Colony-Stimulating Factors; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


53. Colović M, Matić S, Kryeziu E, Tomin D, Colović N, Atkinson HD: Outcomes of primary thyroid non-Hodgkin's lymphoma: a series of nine consecutive cases. Med Oncol; 2007;24(2):203-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of primary thyroid non-Hodgkin's lymphoma: a series of nine consecutive cases.
  • Primary non-Hodgkin's lymphoma (NHL) of the thyroid gland is a rare disease with an incidence of 0.5 per 100,000 population.
  • Stages IE and IIE thyroid NHL have been traditionally treated by surgical resection; however, modern treatment consists of chemotherapy and local radiotherapy, and surgery is often reserved for tissue diagnosis and relief of airway compression.
  • We retrospectively reviewed the management and outcomes of nine consecutive patients with thyroid NHL, eight females and one male (median age 63 yr, range 34-71 yr) treated between 1994 and 1999.
  • Pathohistology and immunohistochemistry identified two patients with mucosa-associated lymphoid tissue (MALT), three follicular center cell lymphoma (FCC), two patients large B-cell lymphoma (BLCL), one a marginal zone lymphoma (MZL), and one patient a peripheral T-cell lymphoma (PTCL).
  • One (MALT) patient underwent surgery alone; three patients surgery, radiotherapy, and chemotherapy (two FCC, one PTCL); three patients surgery and chemotherapy (one MALT, one FCC, one LBCL); and two chemotherapy alone (one LBCL, one MZL).
  • The PTCL patient, a 34-yr-old man, died from disseminated disease at 13 mo despite secondary chemotherapy, and one LBCL patient with extensively invasive local disease died from stroke 17 mo after diagnosis.
  • With appropriate therapy primary thyroid NHL has a favorable course; however, prognosis depends on the histology, local spread, and the stage of the disease at presentation, as well as the patient's performance status.
  • Surgery in combination with chemotherapy and/or radiotherapy is still warranted for intermediate and high-grade thyroid NHLs, with over 77% of patients achieving long-term remission.
  • Peripheral T-cell lymphoma carries a poor prognosis.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy. Thyroid Neoplasms / pathology. Thyroid Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Thyroid Gland / pathology. Thyroid Gland / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2005 Jul;55(7):425-30 [15982218.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):929-33 [1555984.001]
  • [Cites] Acta Oncol. 1996;35(4):457-62 [8695161.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):599-604 [8226154.001]
  • [Cites] Ann Oncol. 2004 May;15(5):821-30 [15111353.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):338-41 [11352307.001]
  • [Cites] N Engl J Med. 1985 Mar 7;312(10):601-4 [3838363.001]
  • [Cites] Am Surg. 1998 Mar;64(3):234-8 [9520813.001]
  • [Cites] Am J Clin Pathol. 1999 Aug;112(2):263-70 [10439808.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Feb;11(2):365-70 [3918965.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Oct;12(10):1813-21 [3759532.001]
  • [Cites] Am J Clin Oncol. 2004 Apr;27(2):178-84 [15057158.001]
  • [Cites] Eur J Surg Oncol. 1992 Aug;18(4):313-21 [1521621.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Oct;12(10):1807-12 [2428787.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1994;6(5):300-4 [7826922.001]
  • [Cites] Cancer. 1994 Jan 1;73(1):200-6 [8275426.001]
  • [Cites] Hum Pathol. 1988 Nov;19(11):1315-26 [3141260.001]
  • [Cites] Radiology. 1969 Mar;92(4):812-6 [5767761.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):623-39 [10800981.001]
  • [Cites] JAMA. 1979 Oct 19;242(16):1743-6 [480599.001]
  • [Cites] Cancer. 1980 Dec 1;46(11):2356-9 [7002279.001]
  • [Cites] Cancer. 1977 Apr;39(4):1587-602 [322838.001]
  • (PMID = 17848745.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Buadi FK, Micallef IN, Ansell SM, Porrata LF, Dispenzieri A, Elliot MA, Gastineau DA, Gertz MA, Lacy MQ, Litzow MR, Tefferi A, Inwards DJ: Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant; 2006 Jun;37(11):1017-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma.
  • To evaluate autologous stem cell transplant (ASCT) in older patients with intermediate grade non-Hodgkin's lymphoma (NHL), the Mayo Clinic Rochester BMT database was reviewed for all patients 60 years of age and older who received ASCT for NHL between September 1995 and February 2003.
  • Factors evaluated included treatment-related mortality (TRM), event-free survival (EFS) and overall survival (OS).
  • Treatment-related mortality (5.4%) was not significantly different when compared to a younger cohort (2.2%).
  • Autologous stem-cell transplant can be safely performed in patients 60 years or older with chemotherapy sensitive relapsed or first partial remission NHL.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Cohort Studies. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633361.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


55. Seropian S, Bahceci E, Cooper DL: Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma. Bone Marrow Transplant; 2003 Oct;32(8):763-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma.
  • A high incidence of nonrelapse mortality (NRM) has limited the use of allogeneic transplantation for poor prognosis non-Hodgkin's lymphoma (NHL).
  • A total of 21 patients with intermediate/high-grade lymphoma and seven patients with low-grade histology were enrolled on protocols using PBSC.
  • Four of the 10 patients with recurrent/persistent disease post transplant responded to additional therapy including withdrawal of immunosuppression+/-DLI.
  • These results support a potent graft-versus-lymphoma effect and suggest that patients who relapse after an autologous transplant can be salvaged with an allogeneic transplant.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / mortality. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Disease-Free Survival. Drug Therapy, Combination. Female. Follow-Up Studies. Graft vs Host Disease / diagnosis. Graft vs Host Disease / drug therapy. Humans. Immunosuppressive Agents / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Recurrence. Risk Factors. Survival Rate. Tacrolimus / administration & dosage. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14520419.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; WM0HAQ4WNM / Tacrolimus; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


56. Taylor CW, LeBlanc M, Fisher RI, Moore DF Sr, Roach RW, Elias L, Miller TP: Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group trial. Anticancer Drugs; 2000 Oct;11(9):695-700
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group trial.
  • We performed a phase II, Southwest Oncology Group (SWOG) clinical trial of recombinant human interleukin-4 (rhuIL-4) in patients with previously treated non-Hodgkin's lymphoma (NHL).
  • We studied 18 eligible patients with low-grade and 21 patients with intermediate- or high-grade NHL.
  • All patients had received prior chemotherapy.
  • A protocol amendment after the first four patients reduced the frequency of s.c. rhuIL-4 administration from daily to 3 times per week at 3 microg/kg and limited the number of prior chemotherapy regimens allowed.
  • We documented no complete or partial responses in the low-grade NHL group [0%; 95% confidence interval (CI) 0-19%].
  • One patient in the intermediate/high-grade NHL group developed a partial response lasting longer than 15 months (5%; 95% CI 0-24%).
  • Median survivals for the low- and intermediate/high-grade NHL groups were 15 and 13 months, respectively.
  • Our previously treated NHL patients tolerated s.c. rhuIL-4 at a dose of 3 microg/kg given 3 times per week, but objective response rarely occurred.
  • [MeSH-major] Interleukin-4 / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Recombinant Proteins / adverse effects. Recombinant Proteins / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11129730.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; etc
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 207137-56-2 / Interleukin-4
  •  go-up   go-down


57. De Sanctis V, Martelli M, Anticoli AP, Caronna R, Chirletti P, Giovannini M, Santarelli M, Enrici RM, Mandelli F: Localized stage I-IE aggressive non-Hodgkin's lymphoma (NHL): results of prospective study with multimodality therapeutic approach. Anticancer Res; 2001 Nov-Dec;21(6A):4169-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized stage I-IE aggressive non-Hodgkin's lymphoma (NHL): results of prospective study with multimodality therapeutic approach.
  • BACKGROUND: A brief course of chemotherapy followed by radiation therapy was considered the best treatment for localized high-grade Non-Hodgkin's Lymphoma (NHL).
  • The purpose of this study was to determine the efficacy and feasibility of a brief-course of anthracycline-based chemotherapy (CHOP) and consolidation radiation therapy (CRT) in a series of 57 consecutive patients with stage I-IE intermediate-high grade NHL.
  • Forty-four (77%) received a CRT and thirteen (23%) with primitive gastric and splenic NHL underwent radical surgery.
  • The 5-year OS, DFS and EFS was 100% in thirteen patients with primitive gastric or splenic NHL treated with a radical surgical approach followed by chemotherapy without CRT.
  • CONCLUSION: We confirm the efficacy and feasibility of a brief course of CHOP chemotherapy followed by CRT in localized I-IE intermediate-high grade NHL without adverse prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prospective Studies. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911313.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] Greece
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


58. Alici S, Bavbek S, Basaran M, Onat H: Prognostic factors in patients with aggressive non-Hodgkin's lymphoma without complete response to first-line therapy. Adv Ther; 2006 Jul-Aug;23(4):534-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in patients with aggressive non-Hodgkin's lymphoma without complete response to first-line therapy.
  • This study was conducted to retrospectively identify the prognostic factors that specifically predict survival rates of patients with aggressive non-Hodgkin's lymphoma who did not achieve a complete response (CR) to first-line therapy.
  • Prognostic factors in terms of survival were analyzed in 76 adult patients with non-Hodgkin's lymphoma who had failed to achieve CR to first-line chemotherapy (CT) regimens administered at Istanbul University, Institute of Oncology, between February 1989 and October 1998.
  • In all, 92% had been administered anthracycline on the basis of computed tomography findings.
  • Of the 49 patients who had a PR to first-line therapy, 31 died because of disease progression.
  • Although median OS was 18.1 mo (range, 8.4-27.8 mo) in patients with intermediate-grade histology, it was 6.1 mo (range, 1-11.7 mo) in patients with highgrade histology (P=.001).
  • As a result of univariate analysis, significant rognostic factors associated with OS included histologic grade (intermediate/high) (P=.001), response to initial therapy (primary refractory disease/PR) (P=.005), performance status (0-2/2-4) (P=.024), and International Prognostic Index risk groups (low/low intermediate/intermediatehigh high risk) (P=.004).
  • Multivariate analysis revealed that independent prognostic parameters associated with OS included response to initial therapy (P=.009) and histologic grade (P=.001).
  • Although prognosis is rather poor in patients with high histologic grade and primary refractory disease, patients with a PR have a slightly better prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17050496.001).
  • [ISSN] 0741-238X
  • [Journal-full-title] Advances in therapy
  • [ISO-abbreviation] Adv Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Misgeld E, Wehmeier A, Krömeke O, Gattermann N: Primary non-Hodgkin's lymphoma of bone: three cases and a short review of the literature. Ann Hematol; 2003 Jul;82(7):440-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of bone: three cases and a short review of the literature.
  • Primary non-Hodgkin's lymphoma of bone (PLB) is a rare entity.
  • Histopathologically, PLB usually represents diffuse large B-cell lymphoma or lymphoma of the follicular center type.
  • Localized stages of the disease require involved-field radiotherapy (45-50 Gy) to the entire bone that is affected.
  • In cases of intermediate or high-grade lymphoma of bone, combined radiochemotherapy is the treatment of choice for all stages.
  • Six to eight cycles of chemotherapy (usually the CHOP regimen) are recommended for remission induction.
  • This is followed by involved-field radiotherapy with 45-50 Gy.
  • High-dose chemotherapy with autologous stem cell support is an option if there is no satisfactory response to conventional chemotherapy, or if early relapse occurs.
  • [MeSH-major] Bone Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnostic Imaging. Female. Humans. Male. Middle Aged. Remission Induction / methods

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12761650.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 22
  •  go-up   go-down


60. Nishioka T, Tsuchiya K, Nishioka S, Kitahara T, Ohmori K, Homma A, Aoyma H, Shindoh M, Shirato H: Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck. Int J Radiat Oncol Biol Phys; 2004 Nov 1;60(3):847-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
  • PURPOSE: To evaluate the safety and efficacy of a modified version of cyclophosphamide, doxorubicin, vincristine, prednisone (pirarubicin, cyclophosphamide, vincristine, and prednisone [THP-COP]) plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
  • METHODS AND MATERIALS: Between December 1993 and December 1999, 41 patients with early-stage non-Hodgkin's lymphoma with intermediate-grade histologic features were enrolled in our study.
  • Chemotherapy consisted of 40 mg/m(2) i.v. pirarubicin (THP-Adriamycin), 750 mg/m(2) i.v. cyclophosphamide, and 1.0 mg/m(2) i.v. vincristine, on Day 1 and 40 mg/m(2) p.o. prednisone on Days 1-5.
  • The combination chemotherapy was given twice at a 14-day interval.
  • Radiotherapy was given to involved areas at a fraction size of 2.0-2.5 Gy up to a total of 40 Gy within 4-5 weeks.
  • Grade 4 neutropenia was seen in 12% of patients; however, 93% of patients (38 of 41) received chemotherapy as scheduled with the support of granulocyte colony-stimulating factor.
  • CONCLUSION: Biweekly THP-COP plus radiotherapy is feasible and effective for Stage I-II low-risk non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Female. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Prednisone / administration & dosage. Recurrence. Survival Rate. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15465202.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol, modified
  •  go-up   go-down


61. Ryan GF, Roos DR, Seymour JF: Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers. Clin Lymphoma Myeloma; 2006 Jan;6(4):337-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers.
  • The breast is an uncommon site of presentation for primary non-Hodgkin's lymphoma, with prognosis and patterns of relapse still not clearly defined.
  • Histology was predominantly intermediate grade, with diffuse large B-cell lymphoma (DLBL) in 16 cases (76%).
  • The most common treatment program was partial mastectomy followed by chemotherapy and radiation therapy (n = 12).
  • Complete response (CR) to treatment was exhibited in 19 patients (90%), 11 of whom subsequently experienced relapse.
  • Including the 2 patients who failed to exhibit an initial CR, the median time to disease progression was 23.4 months (range, 0-143 months), with a 5-year disease-free survival rate of 38% (+/- 12%).
  • [MeSH-major] Breast Neoplasms / mortality. Lymphoma, B-Cell / mortality. Lymphoma, Large B-Cell, Diffuse / mortality. Neoplasm Recurrence, Local / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / mortality. Central Nervous System Neoplasms / prevention & control. Central Nervous System Neoplasms / secondary. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Prognosis. Retrospective Studies. Treatment Failure

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507213.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


62. Yuan ZY, Li YX, Zhao LJ, Gao YH, Liu XF, Gu DZ, Qian TN, Yu ZH: [Clinical features, treatment and prognosis of 136 patients with primary non-Hodgkin's lymphoma of the nasopharynx]. Zhonghua Zhong Liu Za Zhi; 2004 Jul;26(7):425-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features, treatment and prognosis of 136 patients with primary non-Hodgkin's lymphoma of the nasopharynx].
  • OBJECTIVE: To investigate the clinical characteristics, international prognostic index and treatment of primary non-Hodgkin's lymphoma (NHL) of the nasopharynx.
  • METHODS: From January 1983 to December 1997, 136 patients with previously untreated NHL of the nasopharynx were retrospectively reviewed.
  • There were 18 patients with high-grade, 77 intermediate, 2 low-grade and 39 unclassifiable lymphoma.
  • Primary therapy was radiotherapy alone in 13 patients and radiotherapy combined with chemotherapy in 12 patients with stage I disease.
  • In 88 patients with stage II, radiotherapy alone was given to 31 patients, and a combination of radiotherapy and chemotherapy to 57 patients.
  • Chemotherapy was primary treatment for advanced stage III/IV diseases.
  • For stage I patients, the 5-year CSS was 83.1% for RT alone and 82.2% for combined modality therapy, respectively (P = 0.779).
  • For patients with stage II, the 5-year CSS was 46.0% for radiotherapy alone and 70.9% for combined modality therapy.
  • CONCLUSION: International prognostic index is an important prognostic factor for Non-Hodgkin's lymphoma of the nasopharynx and the combined modality therapy may be optimal for the stage II patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Nasopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Child. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prognosis. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15355649.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP-B protocol
  •  go-up   go-down


63. Niitsu N, Okamoto M, Kuraishi Y, Nakamura S, Kodama F, Hirano M: CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: a pilot study. The Adult Lymphoma Treatment Study Group (ALTSG). Eur J Haematol; 2000 Sep;65(3):188-94
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: a pilot study. The Adult Lymphoma Treatment Study Group (ALTSG).
  • We conducted a multi-institutional collaborative study to examine the usefulness and safety of third-generation chemotherapy CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) combined with granulocyte colony-stimulating factor (G-CSF) in the treatment of aggressive non-Hodgkin's lymphoma (NHL).
  • Subjects included patients with aggressive NHL who were 60 yr of age or younger and had been diagnosed as having a low-intermediate, high-intermediate, or high risk using the International Prognostic Index (IPI).
  • A total of 24 patients were enrolled in the study between May 1997 and March 1998, including 9 low-intermediate-risk cases, 13 high-intermediate-risk cases and 2 high-risk cases.
  • Although all 24 patients were originally enrolled in the study, one adult T-cell leukemia/lymphoma case was subsequently excluded.
  • Evaluation of the efficacy of therapy revealed complete remission in 20 patients (87%).
  • Of these 20 patients, 8 were low-intermediate-risk cases (89%) and 12 were either high-intermediate- or high-risk cases (86%).
  • Grade 3 or higher adverse reactions were granulocytopenia (87%), thrombocytopenia (17.4%) and liver dysfunction (4.3%).
  • CyclOBEAP therapy has been associated with a high remission rate for aggressive NHL.
  • When combined with G-CSF, a high relative dose intensity was maintained for each drug administered (0.94-0.97).
  • Hence, we concluded that there were no problems associated with the procedure in terms of safety.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Pilot Projects. Prednisolone / administration & dosage. Prognosis. Remission Induction. Risk Factors. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11007055.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] DENMARK
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; PACEBO protocol
  •  go-up   go-down


64. Mizorogi F, Hiramoto J, Nozato A, Takekuma Y, Nagayama K, Tanaka T, Takagi K: Hepatitis C virus infection in patients with B-cell non-Hodgkin's lymphoma. Intern Med; 2000 Feb;39(2):112-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis C virus infection in patients with B-cell non-Hodgkin's lymphoma.
  • OBJECTIVE: As a causative role of hepatitis C virus (HCV) in B-cell lymphoproliferative disorders (LPD) has been suggested by several reports, we investigated the prevalence of HCV infection among patients with LPD at our hospital with the aim of clarifying the clinical features and the outcome for HCV antibody-positive patients with non-Hodgkin's lymphoma (NHL).
  • PATIENTS: A total of 123 patients with B-cell LPD (4 with chronic lymphocytic leukemia, 17 with multiple myeloma, and 100 with B-cell NHL), 38 patients with non-B-cell LPD (5 with adult T-cell lymphoma, 8 with Hodgkin's disease, and 25 with non-B-cell NHL) and 516 patients with miscellaneous diseases other than liver diseases or LPD (control) were studied.
  • RESULTS: HCV infection was detected in 17 of 100 patients with B-cell NHL versus none of 25 patients with non-B-cell NHL (p=0.023) and in 34 patients (6.6%) in the control group with miscellaneous diseases (p=0.0011).
  • In HCV-positive B-cell NHL, primary liver involvement was detected in 3 of 17 patients compared to none of 83 HCV-negative patients (p=0.0019).
  • Intermediate-grade lymphoma (Working Formulation) was the most frequent histology.
  • Eleven of 15 HCV-positive patients achieved complete remission after chemotherapy, and 6 of 7 deaths were caused by liver-related diseases.
  • CONCLUSION: The prevalence of HCV infection was higher in patients with B-cell NHL than in those with non-B-cell NHL and the control group.
  • Primary liver involvement and liver-related causes of death were frequent in HCV-positive patients with B-cell NHL.
  • [MeSH-major] Hepatitis C / complications. Lymphoma, B-Cell / virology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Enzyme-Linked Immunosorbent Assay. Female. Hepacivirus / genetics. Hepacivirus / immunology. Hepatitis C Antibodies / analysis. Humans. Japan / epidemiology. Male. Middle Aged. Polymerase Chain Reaction. Prevalence. Prognosis. RNA, Viral / analysis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10732826.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Hepatitis C Antibodies; 0 / RNA, Viral
  • [Number-of-references] 24
  •  go-up   go-down


65. Oguchi M, Ikeda H, Isobe K, Hirota S, Hasegawa M, Nakamura K, Sasai K, Hayabuchi N: Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan Lymphoma Radiation Therapy Group. Int J Radiat Oncol Biol Phys; 2000 Aug 1;48(1):161-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan Lymphoma Radiation Therapy Group.
  • PURPOSE: To identify the prognostic factors that specifically predict survival rates of patients with localized aggressive non-Hodgkin's lymphoma (NHL).
  • The 5-year event-free (EFS) and overall survival rates (OAS) were calculated, and univariate and multivariate analyses were done to identify which of the following factors, namely, gender, age, performance status (PS), serum lactate dehydrogenase (LDH) level, Stage (I vs. II), tumor bulk (maximum diameter), and treatment, were significant from the viewpoint of prognosis.
  • RESULTS: A total of 1141 patients with Stage I and II NHL were treated by the Japanese Lymphoma Radiation Therapy Group between 1988 and 1992.
  • Of them, 787 patients, who were treated using definitive radiotherapy with or without chemotherapy for intermediate- and high-grade lymphomas in working formulation, constituted the core of this study.
  • 0001), radiation therapy alone (p < 0.0001), PS = 2-4 (p = 0.0011), (sex male, p = 0.0078), a bulky tumor more than 6 cm in maximum diameter (p = 0.0088), elevated LDH (p = 0.0117), and stage II (p = 0.0642).
  • A median dose of 42 Gy was delivered mainly to the involved fields.
  • Short-course chemotherapy was provided in 549 (70%) patients.
  • Tumor bulk is an important prognostic factor in patients with localized aggressive extranodal NHL.
  • Short course chemotherapy followed by radiation therapy was associated with prolonged survival in patients with localized aggressive NHLs of extranodal origin and 0-1 risk factor.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Japan / epidemiology. Leucovorin / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prognosis. Proportional Hazards Models. Radiation Injuries / etiology. Radiotherapy Dosage. Survival Rate. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10924986.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; MACOP-B protocol
  •  go-up   go-down


66. Gregory SA, Case DC Jr, Bosserman L, Litwak DL, Berry WR, Kalman LA, Belt RJ, Saven A: Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study. Clin Lymphoma; 2003 Sep;4(2):93-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.
  • The safety and efficacy of compressed-cycle (14-day) standard-dose CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) supported with prophylactic recombinant granulocyte colony-stimulating factor (G-CSF; filgrastim) were evaluated in patients with aggressive non-Hodgkin's lymphoma (NHL).
  • Patients with intermediate- or high-grade NHL (Working Formulation groups D-H and J; N = 120), accrued from 25 clinical practices, were given 6 cycles of standard-dose CHOP every 14 days.
  • Of the 720 chemotherapy cycles planned for all patients, 615 (85%) were given on time at full dose.
  • In the 53 patients = 60 years of age, 80% of the chemotherapy cycles were given on time at full dose, with median RDIs similar to those in the entire population.
  • Hematologic toxicity was significant but tolerable, with no treatment-related deaths.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Granulocyte Colony-Stimulating Factor / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14556680.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


67. Sparano JA, Lee S, Chen MG, Nazeer T, Einzig A, Ambinder RF, Henry DH, Manalo J, Li T, Von Roenn JH: Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol; 2004 Apr 15;22(8):1491-500
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494).
  • PURPOSE: To determine the effectiveness of an infusional chemotherapy regimen in patients with HIV-associated lymphoma treated before and after the use of highly active antiretroviral therapy (HAART) in routine clinical practice.
  • PATIENTS AND METHODS: Ninety-eight assessable patients with HIV-associated intermediate- or high-grade non-Hodgkin's lymphoma received cyclophosphamide 200 mg/m(2)/d, doxorubicin 12.5 mg/m(2)/d, and etoposide 60 mg/m(2)/d (CDE) given by continuous intravenous infusion for 4 days (96 hours) every 4 weeks plus filgrastim.
  • Concurrent antiretroviral treatment consisted of the nucleoside analog didanosine in the first 43 patients enrolled before December 1996 (pre-HAART group), or HAART in the remaining 55 patients enrolled after that time (HAART group).
  • At the time of the analysis, 30% in the pre-HAART group were alive compared with 47% in the HAART group; when adjusted for varying length of follow-up, patients in the HAART group had improved OS (P =.039).
  • Patients in the HAART group experienced less grade 4 nonhematologic toxicity (22% v 42%; P =.037), thrombocytopenia (31% v 52%; P =.033), and anemia (9% v 27%; P =.021), and had fewer treatment-associated deaths (0% v 10%; P =.013).
  • CONCLUSION: Infusional CDE is an effective and potentially curative regimen for patients with HIV-associated lymphoma.
  • Patients treated in the HAART era have less chemotherapy-associated toxicity and improved survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Aged. Humans. Middle Aged. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Feb 20;23(6):1328-9; author reply 1329-30 [15718342.001]
  • (PMID = 15084622.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 13650; United States / NCI NIH HHS / CA / CA 14958; United States / NCI NIH HHS / CA / CA 15488; United States / NCI NIH HHS / CA / CA 16116; United States / NCI NIH HHS / CA / CA 17145; United States / NCI NIH HHS / CA / CA 21115; United States / NCI NIH HHS / CA / CA 23318; United States / NCI NIH HHS / CA / CA 66636
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; ACE protocol 1
  •  go-up   go-down


68. Gershanovich ML, Tikhonova VV: [Use of fludarabin in conjunction with other cytostatics in the treatment of non-Hodgkin lymphoma resistant to standard chemotherapy]. Vopr Onkol; 2004;50(5):602-4
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of fludarabin in conjunction with other cytostatics in the treatment of non-Hodgkin lymphoma resistant to standard chemotherapy].
  • The efficacy of all the procedures was determined by morphological pattern and was reported in low- and intermediategrade non-Hodgkin's disease alone.
  • Tentative findings point to the marked efficacy of fludarabin, particularly, in combination with mitoxanthrone, cyclophosphamide and prednisolone for relapse or refractory low- and intermediate-grade non-Hodgkin's disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15715106.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


69. Eser B, Kaplan B, Unal A, Canoz O, Altuntas F, Sari HI, Er O, Ozkan M, Kucuk C, Arar M, Gursoy S, Cetin M: Clinicopathologic characteristics and therapeutic outcomes of primary gastrointestinal non-Hodgkin's lymphomas in central Anatolia, in Turkey. Yonsei Med J; 2006 Feb 28;47(1):22-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics and therapeutic outcomes of primary gastrointestinal non-Hodgkin's lymphomas in central Anatolia, in Turkey.
  • Primary gastrointestinal lymphoma is a common presentation of non-Hodgkin's lymphoma.
  • The aim of this study was to evaluate clinicopathologic characteristics and the therapeutic outcome of primary gastrointestinal non-Hodgkin's lymphoma.
  • We carried out a retrospective analysis of 74 patients who were presented to our center with histopathological diagnosis of primary gastro-intestinal non-Hodgkin's lymphoma between 1990 and 2001.
  • The treatment choice concerning the surgical or non-surgical management was decided by the initially acting physician.
  • Treatment modalities were compared using the parameters of age, sex, histopathological results, stage, and the site of disease.
  • The intermediate and high grade lymphomas constituted 91.9% of the all cases.
  • The three year overall survival rate was better in stage I and II1 patients who were treated with surgery plus chemotherapy (+/-RT) than those treated with chemotherapy alone (93.7% vs. 55.6%, p < 0.05).
  • The stage and presence of B symptoms affected the disease free survival and overall survival significantly, but the histopathologic grade only affected the overall survival.
  • On the basis of these results, we suggest that surgical resection is necessary before chemotherapy in early stage (stage I and II1) patients with gastrointestinal non-Hodgkin's lymphomas because of the significant survival advantage it would bring to the patient.
  • [MeSH-major] Gastrointestinal Diseases / pathology. Gastrointestinal Diseases / therapy. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy / adverse effects. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome. Turkey / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):895-901 [10705011.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1929-34 [10206316.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] Gastric Cancer. 2001;4(3):137-43 [11760079.001]
  • [Cites] Cancer. 2003 May 15;97(10):2462-73 [12733145.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1847-52 [15223645.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Strahlentherapie. 1977 Apr;153(4):218-21 [857349.001]
  • [Cites] Cancer. 1978 Aug;42(2):693-707 [354774.001]
  • [Cites] Cancer. 1980 Jul 1;46(1):215-22 [7388763.001]
  • [Cites] Ann Surg. 1982 Feb;195(2):196-202 [7034661.001]
  • [Cites] Cancer. 1983 Feb 15;51(4):701-11 [6336982.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1983 Jan;9(1):3-9 [6841173.001]
  • [Cites] Cancer. 1984 Jun 1;53(11):2515-24 [6424928.001]
  • [Cites] Cancer. 1984 Dec 1;54(11):2330-7 [6208989.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):1060-73 [3881161.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 Oct;21(10):1195-200 [3841067.001]
  • [Cites] Cancer. 1986 Sep 1;58(5):1162-6 [3731043.001]
  • [Cites] Cancer. 1986 Oct 1;58(7):1389-99 [3755645.001]
  • [Cites] Wien Klin Wochenschr. 1987 Jun 12;99(12):426-30 [3617772.001]
  • [Cites] Lancet. 1988 Feb 6;1(8580):292-3 [2893097.001]
  • [Cites] Semin Oncol. 1988 Apr;15(2):154-69 [3285479.001]
  • [Cites] Cancer. 1988 Oct 15;62(8):1653-7 [3167781.001]
  • [Cites] Lancet. 1988 Nov 12;2(8620):1148-9 [2903367.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1208-17 [2670184.001]
  • [Cites] Br J Cancer. 1989 Nov;60(5):745-50 [2803951.001]
  • [Cites] J R Soc Med. 1989 Nov;82(11):657-60 [2489024.001]
  • [Cites] J Clin Oncol. 1990 Feb;8(2):266-71 [1688927.001]
  • [Cites] Cancer. 1990 Jun 1;65(11):2528-36 [2186852.001]
  • [Cites] Langenbecks Arch Chir. 1990;375(3):151-5 [2355789.001]
  • [Cites] Yonsei Med J. 1990 Jun;31(2):144-55 [2219972.001]
  • [Cites] Gastroenterology. 1991 Nov;101(5):1159-70 [1936785.001]
  • [Cites] Gastroenterology. 1992 May;102(5):1628-38 [1568573.001]
  • [Cites] J Surg Oncol. 1992 Dec;51(4):270-3 [1434660.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):776-82 [8471435.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1662-71 [8253342.001]
  • [Cites] Ann Oncol. 1993 Dec;4(10):839-46 [8117603.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2709-15 [8194010.001]
  • [Cites] Dtsch Med Wochenschr. 1994 Jun 17;119(24):863-8 [8005064.001]
  • [Cites] Radiology. 1994 Aug;192(2):571-6 [8029434.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1673-84 [8040680.001]
  • [Cites] Ann Oncol. 1994 May;5(5):397-400 [8075046.001]
  • [Cites] Hematol Oncol. 1995 May-Jun;13(3):153-63 [7622145.001]
  • [Cites] Eur J Surg. 1997 Nov;163(11):803-13 [9414040.001]
  • [Cites] J Intern Med. 1998 Jul;244(1):71-8 [9698027.001]
  • [Cites] Pathol Res Pract. 2001;197(6):385-93 [11432665.001]
  • (PMID = 16502482.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2687578
  •  go-up   go-down


70. Briggs JH, Algan O, Miller TP, Oleson JR: External beam radiation therapy in the treatment of patients with extranodal stage IA non-Hodgkin's lymphoma. Am J Clin Oncol; 2002 Feb;25(1):34-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External beam radiation therapy in the treatment of patients with extranodal stage IA non-Hodgkin's lymphoma.
  • The purpose of this report was to study the results of external beam radiotherapy for patients with extranodal stage IA non-Hodgkin's lymphoma (NHL).
  • A retrospective review was carried out on 27 patients seen between 1984 and 1998 with stage IA NHL of extranodal sites, and followed up for a minimum of 1 year.
  • Histologic analysis revealed 16 patients with low-grade NHL, 9 with intermediate-grade, and 2 with high-grade.
  • Ten patients received chemotherapy before radiation therapy, and eight of them had a complete response.
  • The remaining 17 patients were treated with external beam radiation therapy alone.
  • Radiation was directed to the involved field at 1.8 Gy to 2.0 Gy per fraction to a median dose of 40 Gy (range: 20-50.4 Gy).
  • A complete response was attained in all 27 patients after radiation therapy.
  • Older age at presentation showed a trend toward worse outcome (p = 0.07), but because of the relatively few events, other factors (radiation dose, grade of disease, sex, or the use of chemotherapy) showed no statistical differences among the patients.
  • External beam radiation therapy is a highly effective treatment for stage IA NHL found in extranodal sites.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Remission Induction. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11823692.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Sharma A, Bajpai J, Raina V, Mohanti BK: HIV-associated non-Hodgkin's lymphoma: experience from a regional cancer center. Indian J Cancer; 2010 Jan-Mar;47(1):35-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated non-Hodgkin's lymphoma: experience from a regional cancer center.
  • AIMS: To analyze clinical features and survival in HIV-associated non-Hodgkin lymphoma (NHL) cases registered at Dr BRA Institute Rotary Cancer Hospital of AIIMS, New Delhi.
  • MATERIALS AND METHODS: We have retrospectively reviewed records of NHL patients registered, from January 2003 to July 2007 to analyze HIV-associated NHL.
  • RESULTS: Seven cases of HIV-associated NHL cases were identified.
  • Three cases had nodal lymphoma and four had extra nodal lymphoma.
  • No primary CNS (PCNSL) lymphoma was seen.
  • All patients were of advanced stages and of intermediate to high-risk group based on international prognostic index (IPI).
  • Six cases had high-grade NHL.
  • HIV infection was diagnosed as part of NHL work-up in five patients.
  • All were planned for chemotherapy with CNS prophylaxis.
  • CONCLUSIONS: These NHL are of higher grade and advanced stage.
  • Response and tolerance to chemotherapy is poor.
  • With HAART, the goal of therapy is durable CR rather than palliation.
  • [MeSH-major] HIV Infections / complications. HIV Infections / mortality. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult


72. Kucuk O, Young ML, Habermann TM, Wolf BC, Jimeno J, Cassileth PA: Phase II trail of didemnin B in previously treated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group (ECOG) Study. Am J Clin Oncol; 2000 Jun;23(3):273-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trail of didemnin B in previously treated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group (ECOG) Study.
  • Patients with non-Hodgkin's lymphoma (NHL) who fail initial therapy have a poor prognosis.
  • We conducted a phase II study to determine the efficacy and toxicity of didemnin B, a non-myelosuppressive marine compound, in patients with NHL who relapsed or progressed after receiving one or two previous chemotherapy regimens.
  • Twenty-nine patients had intermediate or high grade (IG/HG) disease and 22 patients had low grade (LG) disease.
  • Patients with IG/HG disease had a median time to treatment failure (TTF) of 1.6 months and a median survival of 8.0 months.
  • There were five grade V, 12 grade IV, and 57 grade III toxicities.
  • Didemnin B appears to have modest activity in low grade NHL.
  • However, the drug has considerable toxicity in this population of patients.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Depsipeptides. Lymphoma, Non-Hodgkin / drug therapy. Peptides, Cyclic / adverse effects. Peptides, Cyclic / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Remission Induction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10857892.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA06594; United States / NCI NIH HHS / CA / CA13650; United States / NCI NIH HHS / CA / CA23318; etc
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Depsipeptides; 0 / Peptides, Cyclic; 77327-04-9 / didemnins
  •  go-up   go-down


73. McDonald AC, Nicoll JA, Rampling RP: Non-Hodgkin's lymphoma presenting with spinal cord compression; a clinicopathological review of 25 cases. Eur J Cancer; 2000 Jan;36(2):207-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma presenting with spinal cord compression; a clinicopathological review of 25 cases.
  • The aim of this study was to retrospectively examine 25 patients with newly diagnosed non-Hodgkin's lymphoma (NHL) presenting with spinal cord or cauda equina compression as the first symptom that were referred to our department between 1985 and 1996.
  • At presentation 17 patients were non-ambulatory; dual sphincter impairment was found in 9 patients with a further 8 patients having bladder dysfunction only.
  • All patients had a tissue diagnosis.
  • Five low-grade and 20 intermediate or high-grade tumours were identified.
  • In this latter group 4 patients were treated palliatively and the remaining 16 patients received combination chemotherapy and/or radical radiation therapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / complications. Spinal Cord Compression / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10741279.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


74. McCoy AG, Smith EP, Atkinson ME, Baranski B, Kahl BS, Juckett M, Mitchell T, Gangnon R, Longo WL: A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa. Bone Marrow Transplant; 2004 Jan;33(1):19-24
Hazardous Substances Data Bank. THIO-TEPA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa.
  • The purpose of this study was to evaluate the efficacy and toxicity of the preparative regimen of thiotepa and etoposide in patients undergoing autologous transplantation for relapsed non-Hodgkin's lymphoma.
  • The study involved 65 consecutive patients who underwent autologous transplantation using the thiotepa/etoposide regimen for relapsed intermediate-grade NHL at the University of Wisconsin Hospital and Clinics (UWHC) between 1987 and 2001.
  • The median age at the time of transplant was 49 years.
  • A total of 50 patients (76%) had diffuse large-cell lymphoma.
  • With a median follow-up of 34 months (range, 3-163), 28 patients (43%) remain in CR and 33 (51%) have developed recurrent or progressive disease.
  • [MeSH-major] Etoposide / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Non-Hodgkin / therapy. Thiotepa / administration & dosage. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / toxicity. Drug Resistance, Neoplasm. Female. Gastrointestinal Diseases / chemically induced. Humans. Male. Middle Aged. Remission Induction. Salvage Therapy / methods. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14704653.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 905Z5W3GKH / Thiotepa
  •  go-up   go-down


75. Gregory SA, Vose J, Modiano M, Kraemer K, Rifkin R, Rubin A, Menduni T, Ghalie R: Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen. Leuk Lymphoma; 2001 Jan;40(3-4):315-24
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.
  • Patients with recurrent lymphoma of any grade were treated with mitoxantrone (12 mg/m2 given intravenously (IV) over 15-30 minutes on day 1) followed by fludarabine at a dose of (25 mg/m 2 given IV over 30 minutes on days 1-3) every 28 days fludarabine at a dose of (25 mg/m2 given IV over 30 minutes on days 1-3) every 28 days.
  • All patients had failed one prior chemotherapy regimen that contained either doxorubicin or mitoxantrone, total dose not exceeding 350 mg/m2 doxorubicin or 80 mg/m2 mitoxantrone. mitoxantrone.
  • Thirty one patients (22 with intermediate- or high-grade and 9 with low-grade NHL) were enrolled.
  • The objective response rate for patients with intermediate/high-grade NHL was 55% (27% with CR) and 89% (56% with CR) for patients with low-grade NHL.
  • Median time to disease progression was 5.1 months for patients with intermediate/high-grade NHL and 10.8 months for patients with low-grade NHL.
  • Median time to death for patients with intermediate/high-grade disease was 11.4 months.
  • Median time to death for patients with low-grade NHL was not calculable as only one death (due to respiratory failure) occurred in this group 6.5 months after study start.
  • Grade 3/4 neutropenia was reported in 80% (24 of 30) of patients and Grade 3/4 thrombocytopenia in 19% (6 of 31) of patients.
  • Nine hospitalizations for adverse events (primarily fever and neutropenia) occurred among eight patients, all with intermediate/high-grade NHL, during a total of 118 cycles of therapy.
  • Further studies of this combination regimen in patients with intermediate/high-grade NHL and studies combined with monoclonal antibodies in low-grade NHL are warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Mitoxantrone / administration & dosage. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Disease-Free Survival. Doxorubicin. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Salvage Therapy. Survival Rate. Treatment Failure

  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11426553.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 80168379AG / Doxorubicin; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


76. Singh RK, Varney ML, Ino K, Vose JM, Bierman PJ, Talmadge JE: Immune dysfunction despite high levels of immunoregulatory cytokine gene expression in autologous peripheral blood stem cell transplanted non-Hodgkin's lymphoma patients. Exp Hematol; 2000 May;28(5):499-507
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune dysfunction despite high levels of immunoregulatory cytokine gene expression in autologous peripheral blood stem cell transplanted non-Hodgkin's lymphoma patients.
  • OBJECTIVE: In the present studies, we examined the role of immunoregulatory cytokine gene expression in immune reconstitution following high-dose chemotherapy and peripheral stem cell transplantation.
  • MATERIALS AND METHODS: We analyzed the steady-state mRNA cytokine levels and the immune phenotype and function in the peripheral blood mononuclear cells from intermediate-grade non-Hodgkin's lymphoma patients prior to and following high-dose chemotherapy and peripheral stem cell transplantation.
  • RESULTS: Significantly higher mRNA levels of both type 1 and type 2 cytokines and monokines were observed in patients undergoing high-dose chemotherapy and peripheral stem cell transplantation as compared with normal healthy individuals.
  • However, T-cell function is significantly depressed compared with normal donors, which is associated with significantly higher levels of cellular-dependent T cell inhibitory activity and, we suggest herein, high levels of interleukin-10, a type 2 cytokine.
  • [MeSH-major] Cytokines / genetics. Hematopoietic Stem Cell Transplantation. Lymphocytes / immunology. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / therapy. Transcription, Genetic. Transplantation, Autologous / immunology
  • [MeSH-minor] Adult. Aged. Antigens, CD / blood. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Cells, Cultured. Combined Modality Therapy. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Hematopoietic Stem Cell Mobilization. Humans. Immunophenotyping. Lymphocyte Activation. Male. Middle Aged. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10812239.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA61593; United States / NCI NIH HHS / CA / R29CA72781
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Cytokines; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


77. Kiss TL, Panzarella T, Messner HA, Meharchand J, Reddy V, Schimmer AD, Lipton JH: Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant; 2003 Jan;31(2):73-8
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma.
  • This study reports on overall and recurrence-free survival (OS and RFS) of 37 consecutive patients with low- and intermediate-grade NHL receiving a related donor allogeneic BMT using a nonradiation-containing preparative regimen.
  • A total of 25 patients had low-grade, and 12 intermediate grade NHL.
  • Most patients (89%) were treated with at least two different chemotherapy regimens prior to BMT.
  • Seven patients (19%) died, six because of treatment-related toxicity and one with relapse.
  • Univariate analysis showed improved OS for younger patients and patients of female gender, suggesting that allogeneic BMT using busulfan-cyclophosphamide as a preparative regimen can achieve disease control and possibly cure patients with NHL particularly younger ones.
  • [MeSH-major] Bone Marrow Transplantation. Busulfan / therapeutic use. Cyclophosphamide / therapeutic use. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Follow-Up Studies. Graft vs Host Disease / epidemiology. Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Recurrence. Retrospective Studies. Survival Analysis. Time Factors. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12621486.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  •  go-up   go-down


78. Portlock CS, Qin J, Schaindlin P, Roistacher N, Myers J, Filippa D, Louie D, Zelenetz AD, O'Brien JP, Moskowitz C, Norton L, Yahalom J, Straus DJ, Bertino JR: The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide. Ann Oncol; 2004 Oct;15(10):1495-503
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.
  • BACKGROUND: The NHL-15 protocol is a novel, dose-intense, dose-dense, sequential chemotherapy program developed to improve outcome in advanced, aggressive non-Hodgkin's lymphomas.
  • PATIENTS AND METHODS: The phase II NHL-15 protocol comprised: (i) induction [doxorubicin 60 mg/m(2) i.v. on weeks 1, 3, 5 and 7 plus vincristine 1.4 mg/m(2) i.v. (no cap) on weeks 1, 2, 3, 5 and 7]; and (ii) consolidation (cyclophosphamide 3000 mg/m(2) i.v. on weeks 9, 11 and 13 plus granulocyte colony-stimulating factor 5 microg/kg subcutaneous on days 3-10 following each cyclophosphamide dose).
  • Patients with aggressive non-Hodgkin's lymphomas (working formulation: intermediate grade or immunoblastic), bulky stage I and stages II-IV, were eligible.
  • Acute and late toxicities of treatment were manageable and acceptable.
  • Toxic death on treatment was 2.4%.
  • When the diffuse large cell lymphoma histologies were grouped according to the International Prognostic Index (IPI), complete remission and OS in the low-intermediate (LI), and high-intermediate (HI) risk groups were improved by 5%-15% compared with historical CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone).
  • CONCLUSIONS: The NHL-15 program can be administered safely and effectively to achieve high rates of durable remission when used for the treatment of advanced stage, aggressive, non-Hodgkin's lymphomas.
  • Further evaluation and prospective testing of the NHL-15 protocol appears to be warranted.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15367410.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA05826; United States / NCI NIH HHS / CA / R01 CA61522
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


79. Fu X, Yu D, Mao Y, Yang X, He J, Ke Y, Yang L, Jiang H, Wu C, Deng H: [Clinical study of P-gp, and bcl-2 protein expression in non-Hodgkin's lymphomas patients]. Zhonghua Xue Ye Xue Za Zhi; 2001 Jun;22(6):310-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of P-gp, and bcl-2 protein expression in non-Hodgkin's lymphomas patients].
  • OBJECTIVE: To investigate the relationship between the expression of P-gp, P26-bcl-2 and the prognosis in intermediate and high grade non-Hodgkin's lymphomas (NHL).
  • METHODS: Sixty cases of intermediate and high grade NHL were retrospectively reviewed using immunohistochemical method.
  • All patients were received CHOP chemotherapy over 4 courses.
  • CONCLUSIONS: There is direct relationship between the P-gp, P26-bcl-2 protein expression and the prognosis in intermediate and high grade non-Hodgkin's lymphoma.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Lymphoma, Non-Hodgkin / genetics. P-Glycoprotein / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11877091.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


80. Itoh K, Ohtsu T, Fukuda H, Sasaki Y, Ogura M, Morishima Y, Chou T, Aikawa K, Uike N, Mizorogi F, Ohno T, Ikeda S, Sai T, Taniwaki M, Kawano F, Niimi M, Hotta T, Shimoyama M, Tobinai K, Members of the lymphoma study group of the Japan Clinical Oncology Group (JCOG): Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505. Ann Oncol; 2002 Sep;13(9):1347-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
  • BACKGROUND: CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) is accepted as the best available standard treatment for first-line chemotherapy in aggressive non-Hodgkin's lymphoma (NHL).
  • However, the therapeutic efficacy of CHOP remains unsatisfactory, particularly in high-intermediate risk and high risk patients, and a new strategy is warranted in this patient population.
  • The aim of the present study was to explore a suitable therapeutic-intensified regimen for the treatment of aggressive NHL.
  • PATIENTS AND METHODS: Between May 1995 and July 1998, a total of 70 patients with high-intermediate risk or high risk aggressive NHL, according to the International Prognostic Index, were enrolled and randomly assigned to receive either eight cycles of standard CHOP (cyclophosphamide 750 mg/m(2), doxorubicin 50 mg/m(2), vincristine 1.4 mg/m(2) and prednisolone 100 mg for 5 days) every 2 weeks, or six cycles of dose-escalated CHOP (cyclophosphamide 1500 mg/m(2), doxorubicin 70 mg/m(2), vincristine 1.4 mg/m(2) and prednisolone 100 mg for 5 days) every 3 weeks.
  • The major toxicity was grade 4 neutropenia and was more frequent in the dose-escalated CHOP arm (86%) than in the biweekly CHOP arm (50%).
  • Grade 4 thrombocytopenia was also more frequent in the dose-escalated CHOP arm (20%) than the biweekly CHOP arm (3%).
  • Non-hematological toxicities were acceptable in both arms.
  • One treatment-related death (due to cardiac arrhythmia) was observed in a dose-escalated CHOP patient.
  • CONCLUSIONS: Similar complete response rates and progression-free survival rates, but lower toxicity, indicated that biweekly CHOP was superior to dose-escalated CHOP in the treatment of aggressive NHL.
  • Based on these results, the Lymphoma Study Group of the Japan Clinical Oncology Group is conducting a randomized phase III study comparing biweekly CHOP with standard CHOP in newly diagnosed patients with advanced-stage aggressive NHL.

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2002 Sep;13(9):1329-30 [12196356.001]
  • (PMID = 12196359.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6WS4C399GB / lenograstim; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


81. Casasnovas RO, Haioun C, Dumontet C, Gabarre J, Richard B, Lederlin P, Caillot D, Stamatoullas A, Morel P, Quesnel B, Blay JY, Bouabdallah K, Gisselbrecht C: Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. Haematologica; 2000 May;85(5):502-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
  • BACKGROUND AND OBJECTIVE: The first clinical studies of paclitaxel as a single agent for the treatment of relapsed or refractory low or intermediate grade non-Hodgkin's lymphomas (NHL) yielded controversial results regarding the response rates observed, mainly related to the dose and schedule of administration used.
  • To obtain additional data concerning the efficacy and toxicity of paclitaxel in intermediate and high grade NHL we initiated a phase II study using a 3-hour infusion of high doses of paclitaxel.
  • DESIGN AND METHODS: The eligibility criteria included patients with relapsed or refractory aggressive NHL, a performance status < or = 2 (WHO index), a platelet count > or = 100,000/microL, a neutrophil count > or = 2,000/microL, measurable disease, and adequate hepatic function.
  • Responses were observed in intermediate grade (n = 4) as well as in high grade lymphoma (n = 2).
  • The main factor influencing the response to paclitaxel was the median duration of response to previous chemotherapy regimens which was 3 times longer in patients who responded to paclitaxel (16.3 months) than in patients who did not respond to paclitaxel (5.2 months) (p<0.05).
  • The most common serious side effects were related to the hematologic toxicity of paclitaxel, and included grade IV granulocytopenia in 20 cases (48%), grade III/IV thrombocytopenia in 14 cases (33%) and grade III-IV anemia in 13 cases (31%).
  • However, the clinical efficiency as a single therapy seems modest in relapsed or refractory aggressive lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Paclitaxel / administration & dosage. Paclitaxel / toxicity
  • [MeSH-minor] Adolescent. Adult. Aged. Agranulocytosis / chemically induced. Agranulocytosis / drug therapy. Anemia / chemically induced. Anemia / therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / toxicity. Disease-Free Survival. Drug Evaluation. Female. Hemorrhage / chemically induced. Humans. Infection / chemically induced. Infusions, Intravenous. Male. Middle Aged. Recurrence. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10800167.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] ITALY
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


82. Ambulkar I, Nair R: Primary ovarian lymphoma: report of cases and review of literature. Leuk Lymphoma; 2003 May;44(5):825-7
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for ovarian lymphoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian lymphoma: report of cases and review of literature.
  • We report two cases with primary ovarian non Hodgkin's lymphoma (NHL) having unilateral involvement in one case while the other had bilateral ovarian involvement.
  • Histologically, by using the WHO classification, one lesion was classified as diffuse small B cell phenotype of intermediate grade and the other as diffuse high grade, B cell phenotype.
  • Both of the patients are disease free at 24 months and 6 months of follow up respectively, following excision and chemotherapy.
  • We conclude that that the complete remission and failure free survival of patients with ovarian NHL treated with appropriate treatment appear to be similar to that of patients with extranodal NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / surgery. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / surgery. Remission Induction / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12802921.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 21
  •  go-up   go-down


83. DiBiase SJ, Grigsby PW, Guo C, Lin HS, Wasserman TH: Outcome analysis for stage IE and IIE thyroid lymphoma. Am J Clin Oncol; 2004 Apr;27(2):178-84
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome analysis for stage IE and IIE thyroid lymphoma.
  • Previous reports have revealed modest results in the management of thyroid lymphoma with radiotherapy alone.
  • This retrospective report evaluates the outcome of patients treated for thyroid lymphoma with radiotherapy alone and with combined modality therapy (chemotherapy and radiotherapy) at a single institution.
  • Twenty-seven patients with stages IE and IIE non-Hodgkin's lymphoma of the thyroid gland were treated between 1960 and 1998 at Barnes-Jewish Hospital, of which 14 patients were stage IE and 13 patients were stage IIE.
  • The median follow-up time was 38 months (range: 3-279 months).
  • All patients had histologically proven non-Hodgkin's lymphoma, of which 22 patients (81%) were intermediate grade.
  • Treatment consisted of radiotherapy alone in 19 patients and a combined modality therapy in 8 patients.
  • The median radiation dose to the thyroid bed was 44 Gy, and most patients received a doxorubicin-containing regimen administered prior to radiotherapy.
  • Patient, tumor, and treatment-related characteristics were evaluated using Cox regression analysis.
  • Primary thyroid gland lymphomas have a favorable outcome with appropriate therapy, but prognosis depends on both clinical stage and age at presentation.
  • Because of the risk of both local-regional and distant failure, combined modality approaches that use chemotherapy with radiotherapy are warranted for intermediate- and high grade thyroid lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy. Thyroid Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisolone / administration & dosage. Proportional Hazards Models. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15057158.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


84. Ko AH, Yuen AR: Clinical outcomes associated with very late relapses in diffuse large cell lymphoma. Leuk Lymphoma; 2002 Sep;43(9):1789-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes associated with very late relapses in diffuse large cell lymphoma.
  • While the majority of patients achieve complete remission (CR) following treatment for diffuse intermediate-grade and immunoblastic non-Hodgkin's lymphoma, many will eventually relapse.
  • It is known that late-relapsing patients have a better prognosis than those who relapse earlier; however, the optimal choice of therapy and clinical outcomes in this former group remain uncertain.
  • We report here our experience with patients who develop a very late relapse of their disease, defined as occurring in the fifth year or later from the time of original diagnosis following a period of continuous CR.
  • The overall poor prognosis in this group of patients justifies the use of more aggressive treatment approaches in the future, such as high dose therapy with stem cell support, rather than conventional salvage chemotherapy regimens.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy
  • [MeSH-minor] Adult. Aged. Databases as Topic. Disease-Free Survival. Female. Humans. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Prognosis. Recurrence. Salvage Therapy. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12685833.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


85. Fenske TS, Kahl BS, Eickhoff J, Mitchell TL, Smith EP, Atkinson E, McCoy AG, Eckstein L, Flynn B, McMannes J, Howard S, Longo WL: Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: Long-term autologous transplantation experience in follicular and mantle cell lymphoma. Leuk Lymphoma; 2005 Oct;46(10):1441-8
Hazardous Substances Data Bank. THIO-TEPA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: Long-term autologous transplantation experience in follicular and mantle cell lymphoma.
  • We recently described a novel thiotepa plus etoposide high-dose therapy (HDT) conditioning regimen for aggressive histology non-Hodgkin's lymphoma (NHL) that had low regimen-related toxicity (RRT) and an efficacy rate comparable to other NHL HDT regimens.
  • Between 1992 and 1999, 28 patients with indolent or mantle cell lymphoma were treated on this protocol.
  • The median number of grade 3 - 4 non-hematologic toxicities was five.
  • In contrast, the thiotepa + etoposide conditioning regimen (without TBI or IFRT) given to 65 intermediate grade NHL patients resulted in only one treatment-related death and considerably fewer grade 3 - 4 toxicities.
  • Given the relatively short EFS in this cohort of indolent NHL patients, we conclude that the combination of IFRT and TBI plus thiotepa and etoposide resulted in a HDT regimen with excessive toxicity and this protocol was closed at our institution.
  • [MeSH-major] Etoposide / adverse effects. Hematopoietic Stem Cell Transplantation. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / radiotherapy. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Mantle-Cell / radiotherapy. Thiotepa / adverse effects
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / adverse effects. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Rate. Time Factors. Transplantation, Autologous


86. Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L: Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol; 2005 May;52(5):847-53
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary cutaneous B-cell lymphoma with rituximab.
  • Intravenous administration of rituximab has been used for the treatment of patients with low-, intermediate-, and high-grade B-cell non-Hodgkin's lymphomas and is a registered treatment modality for this indication.
  • Treatment of primary cutaneous B-cell lymphoma (CBCL) with intralesionally or systemically administered rituximab has been described only in a few cases.
  • OBJECTIVE: Our purpose was to assess the efficacy of rituximab in the treatment of CBCL.
  • Complete remission could be observed in 6 of 7 patients after 1 to 8 cycles of intralesional treatment with rituximab.
  • In one patient one of two lesions showed a partial remission after 4 cycles of treatment, whereas the second showed complete remission.
  • A local recurrence was observed in one patient after 27 months of follow-up and in two patients recurrences developed at other body sites after 12 and 14 months of follow-up.
  • CONCLUSION: Rituximab therapy is a well-tolerated and effective treatment for primary CBCL.
  • In comparison to intravenous administration, intralesional application of the drug allows the use of lower dosages.
  • Intralesional therapy with rituximab deserves further investigation and comparison to systemic administration of the drug in controlled multicenter studies.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / analysis. Female. Humans. Injections, Intralesional. Injections, Intravenous. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Rituximab

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858476.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


87. Sarkodee-Adoo C, Pittarelli L, Jaffe E, Sorbara L, Raffeld M, Yao X, Haddad R, Heller T: Regression and clonally distinct recurrence of human immunodeficiency virus related Burkitt-like lymphoma during antiretroviral therapy. Leuk Lymphoma; 2001 Sep-Oct;42(5):1125-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression and clonally distinct recurrence of human immunodeficiency virus related Burkitt-like lymphoma during antiretroviral therapy.
  • An increased incidence of intermediate to high-grade Non Hodgkin's Lymphoma is found in individuals with AIDS.
  • Although immune function in AIDS patients can be improved through the use of antiretroviral therapy, the contribution of these drugs to lymphoma regression is not known.
  • Here we describe the complete regression and subsequent recurrence of high grade, Burkitt-like lymphoma during antiretroviral therapy in a patient with AIDS.
  • Antiretroviral therapy resulted in diminished viral load and modest improvement in CD4+ T cell counts.
  • Lymphoma regressed initially, but relapsed 3 months later.
  • Tissue taken from the initial and recurrent tumor demonstrated different clonal rearrangements.
  • The recurrent lymphoma did not respond to continued antiretroviral therapy.
  • In Conclusion, antiretroviral therapy may contribute to lymphoma regression in AIDS lymphoma.
  • [MeSH-major] Anti-HIV Agents / administration & dosage. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / pathology
  • [MeSH-minor] Adult. Burkitt Lymphoma. Clone Cells / pathology. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Male. Neoplasms, Second Primary / pathology. Recurrence. Remission Induction

  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11697632.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


88. Thyagarajan MS, Dobson MJ, Biswas A: Case report: appearance of uterine cervical lymphoma on MRI: a case report and review of the literature. Br J Radiol; 2004 Jun;77(918):512-5
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: appearance of uterine cervical lymphoma on MRI: a case report and review of the literature.
  • We present the appearances on CT and MRI of a case of non-Hodgkin's lymphoma (NHL) of uterine cervix.
  • Biopsy showed malignant high grade B-cell NHL.
  • T(2) weighted MRI of the pelvis showed a 12 cm intermediate signal mass replacing the cervix, with infiltration of the vagina and left parametrium, and bilateral internal iliac lymphadenopathy.
  • Whole body CT imaging showed lymphoma in the kidneys and pancreas, the latter associated with biliary obstruction.
  • The patient is in complete remission 7 months post chemotherapy, radiotherapy and stenting of biliary stricture.
  • The success of the cervical cancer screening programme has lead to a reduction in the number of cases of advanced cervical carcinoma and the presence of an unusually large homogeneous cervical tumour, with relatively scant necrosis should prompt suspicion of a less common histology such as NHL.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15151974.001).
  • [ISSN] 0007-1285
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 30
  •  go-up   go-down


89. Demirer T, Ayli M, Fen T, Ozcan M, Arat M, Buyukberber S, Arslan O, Gurman G, Akan H, Ilhan O: High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation. Bone Marrow Transplant; 2004 Nov;34(9):781-6
Hazardous Substances Data Bank. THIO-TEPA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation.
  • The purpose of this evaluation was to investigate the efficacy of high-dose chemotherapy with thiotepa, melphalan, and carboplatin (TMCb), and of autologous peripheral blood stem cell (PBSC) infusion in patients with aggressive non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD).
  • A total of 42 patients, 23 with intermediate-grade NHL and 19 with HD, received thiotepa (500 mg/m2), melphalan (100 mg/m2), and carboplatin (1050-1350 mg/m2) followed by autologous PBSC infusion.
  • Grade 3-4 regimen-related toxicities (RRT) occurred in five of 42 (12%) patients and death due to grade-4 RRT occurred in only one (2.5%) patient.
  • These preliminary data suggest that 0.42% EFS in this study for advanced disease patients is highly encouraging and high-dose TMCb followed by autologous PBSC transplantation is well tolerated as well as an effective regimen in patients with intermediate-grade NHL or HD, and may be comparable to some previously used regimens including TBI-based regimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma / therapy. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Male. Melphalan / administration & dosage. Middle Aged. Retrospective Studies. Survival Analysis. Thiotepa / administration & dosage. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15354206.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 905Z5W3GKH / Thiotepa; BG3F62OND5 / Carboplatin; Q41OR9510P / Melphalan
  •  go-up   go-down


90. Deconinck E, Lamy T, Foussard C, Gaillard F, Delwail V, Colombat P, Casassus P, Lemevel A, Brion A, Milpied N: Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br J Haematol; 2000 Jun;109(4):736-42
Hazardous Substances Data Bank. PODOFILOX .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Autologous stem cell transplantation (ASCT) in the front line treatment of non-Hodgkin's lymphoma (NHL) remains controversial.
  • Anaplastic large-cell lymphoma (ALCL) is known to have its own clinical and biological features.
  • The outcome of ALCL patients treated with high-dose chemotherapy and ASCT as part of their first-line therapy was analysed in 202 intermediate or high-grade NHL patients in a prospective randomized trial.
  • First-line chemotherapy comprised two alternating anthracycline-containing regimens.
  • Anaplastic lymphoma kinase (ALK) expression was confirmed in seven cases.
  • These results differ significantly from those observed in the other 176 lymphoma patients: event-free survival was only 53 +/- 5% and OS reached 60 +/- 4% with a median follow-up of 56 months (P = 0.006).
  • Intensified chemotherapy with autologous stem cell support appeared effective in the treatment of ALCL, offering patients the real chance of a cure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Large B-Cell, Diffuse / surgery
  • [MeSH-minor] Adolescent. Adult. Antibiotics, Antineoplastic / administration & dosage. Carmustine / administration & dosage. Combined Modality Therapy. Cytarabine / administration & dosage. Disease-Free Survival. Female. Humans. Male. Melphalan / administration & dosage. Middle Aged. Podophyllotoxin / administration & dosage. Prospective Studies. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10929023.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 04079A1RDZ / Cytarabine; L36H50F353 / Podophyllotoxin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM protocol
  •  go-up   go-down


91. Gurkaynak M, Cengiz M, Akyurek S, Ozyar E, Atahan IL, Tekuzman G: Waldeyer's ring lymphomas: treatment results and prognostic factors. Am J Clin Oncol; 2003 Oct;26(5):437-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Waldeyer's ring lymphomas: treatment results and prognostic factors.
  • Optimal management of patients with localized Waldeyer's ring (WR) lymphoma remains controversial due to the lack of randomized studies and heterogenous grouping of most reported series.
  • In this retrospective study, we have evaluated the possible prognostic factors and treatment outcome of WR non-Hodgkin's lymphoma.
  • Between December 1993 and February 2000, 32 patients with WR lymphoma, stage I (11 patients) and stage II (21 patients) were treated.
  • According to Working Formulation, 10 had high-grade, 17 intermediate grade, 3 low-grade, and 2 had unclassified lymphomas.
  • Combined chemotherapy and radiotherapy was the primary modality of therapy for intermediate or high-grade lymphoma.
  • Radiotherapy alone was employed only in low-grade WR lymphomas.
  • Chemotherapy was median 6 courses of CHOP (cyclophosphamide, doxorubicin (Adriamycin), vincristine, and prednisolone) in 26 patients and CEOP (cyclophosphamide, doxorubicin, etoposide, and prednisone).
  • Radiotherapy volume was involved field and the median dose was 40 Gy.
  • Two patients developed recurrence, both salvaged with further chemotherapy.
  • Our results suggest that combined chemotherapy and involved field radiotherapy is appropriate treatment for stage I-II WR lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / mortality. Nasopharyngeal Neoplasms / mortality. Tongue Neoplasms / mortality. Tonsillar Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14528067.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Drapkin R: Pentostatin and rituximab in the treatment of patients with B-cell malignancies. Oncology (Williston Park); 2000 Jun;14(6 Suppl 2):25-9
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pentostatin and rituximab in the treatment of patients with B-cell malignancies.
  • Both pentostatin (Nipent) and rituximab (Rituxan) have single-agent activity in B-cell malignancies, including indolent and intermediate-grade non-Hodgkin's lymphoma (NHL).
  • In spite of current treatment modalities, few patients with these diseases are cured.
  • The combination of rituximab and pentostatin is an attractive treatment option because both drugs have a limited toxicity profile and can be delivered on an outpatient basis.
  • We describe the design of a phase II multicenter study to evaluate the safety and efficacy of pentostatin in combination with rituximab in patients with previously treated and untreated low-grade NHL and CLL.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, B-Cell / drug therapy. Pentostatin / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Clinical Trials, Phase II as Topic. Female. Humans. Male. Middle Aged. Rituximab. Treatment Outcome

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10887641.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Multicenter Study
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 395575MZO7 / Pentostatin; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


93. Singh RK, Varney ML, Leutzinger C, Vose JM, Bierman PJ, Buyukberber S, Ino K, Loh K, Nichols C, Inwards D, Rifkin R, Talmadge JE: Immune reconstitution after autologous hematopoietic transplantation with Lin-, CD34+, Thy-1lo selected or intact stem cell products. Int Immunopharmacol; 2007 Aug;7(8):1033-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In sequential studies, we compared immune reconstitution following high-dose chemotherapy (HDT) and stem cell transplantation (SCT) using intact mobilized peripheral blood stem cell (PSC) in intermediate grade non-Hodgkin's lymphoma (NHL) patients and CD34(+), lineage-negative (Lin(-)), Thy-1(lo) (CD34(+)Lin(-)Thy-1(lo)) stem cells in low-grade NHL patients.
  • Significantly higher levels of type 1- and 2-associated cytokine messenger ribonucleic acid (mRNA) were observed both prior to and following transplant in the peripheral blood (PB) of both cohorts as compared to normal individuals.
  • In contrast, patients receiving isolated CD34(+)Lin(-)Thy-1(lo) cells expressed significantly higher IL-2 levels at all times examined post-transplant.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cancer Biol. 2006 Feb;16(1):53-65 [16168663.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4794-803 [16914564.001]
  • [Cites] Br J Haematol. 2006 Oct;135(1):76-84 [16925797.001]
  • [Cites] Semin Hematol. 2006 Oct;43(4):240-50 [17027658.001]
  • [Cites] Clin Adv Hematol Oncol. 2006 Jul;4(7):521-30 [17147239.001]
  • [Cites] Haematologica. 1999 Dec;84(12):1100-3 [10586212.001]
  • [Cites] Eur J Surg Oncol. 2000 Feb;26(1):30-3 [10718176.001]
  • [Cites] Exp Hematol. 2000 Jul;28(7):858-70 [10907648.001]
  • [Cites] Hematol Oncol. 2000 Sep;18(3):111-20 [11027980.001]
  • [Cites] Bone Marrow Transplant. 2000 Nov;26(9):971-7 [11100276.001]
  • [Cites] J Hematother Stem Cell Res. 2000 Oct;9(5):727-36 [11091497.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2514-21 [11290617.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3851-9 [11389026.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7(12):680-7 [11787531.001]
  • [Cites] Int Immunopharmacol. 2003 Aug;3(8):1121-43 [12860168.001]
  • [Cites] Curr Hematol Rep. 2004 Jul;3(4):257-64 [15217555.001]
  • [Cites] Cancer Immunol Immunother. 2004 Oct;53(10):865-78 [15118842.001]
  • [Cites] Blood. 1984 Aug;64(2):380-5 [6378275.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Transplantation. 1989 May;47(5):871-6 [2655225.001]
  • [Cites] Blood. 1989 Nov 1;74(6):2270-7 [2572284.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1621-9 [2809678.001]
  • [Cites] N Engl J Med. 1991 Nov 28;325(22):1525-33 [1944436.001]
  • [Cites] Blood. 1991 Dec 1;78(11):3076-80 [1954393.001]
  • [Cites] Blood. 1992 May 15;79(10):2694-700 [1316784.001]
  • [Cites] Bone Marrow Transplant. 1992 Apr;9(4):285-91 [1376185.001]
  • [Cites] Leuk Res. 1992 Jun-Jul;16(6-7):607-13 [1386130.001]
  • [Cites] Bone Marrow Transplant. 1993 Jan;11(1):15-20 [8381694.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3107-11 [10397252.001]
  • [Cites] Bone Marrow Transplant. 1999 Jul;24(2):153-61 [10455343.001]
  • [Cites] Bone Marrow Transplant. 1999 Aug;24(3):295-302 [10455369.001]
  • [Cites] Bone Marrow Transplant. 2005 Mar;35 Suppl 1:S53-7 [15812532.001]
  • [Cites] Exp Hematol. 2005 Aug;33(8):912-9 [16038784.001]
  • [Cites] Semin Cancer Biol. 2006 Feb;16(1):3-15 [16153857.001]
  • [Cites] Cancer Immunol Immunother. 1993 Nov;37(6):408-11 [8242665.001]
  • [Cites] Bone Marrow Transplant. 1993 Nov;12(5):469-75 [7905331.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1177-84 [8201380.001]
  • [Cites] Bone Marrow Transplant. 1994 Feb;13(2):187-95 [8205088.001]
  • [Cites] Bone Marrow Transplant. 1994 Apr;13(4):411-5 [7517258.001]
  • [Cites] Ann N Y Acad Sci. 1994 May 31;716:204-14; discussion 214-5, 225-7 [8024195.001]
  • [Cites] J Hematother. 1993 Spring;2(1):7-17 [7522875.001]
  • [Cites] In Vivo. 1994 Nov-Dec;8(5):675-90 [7727713.001]
  • [Cites] Blood. 1995 Jul 1;86(1):381-9 [7540887.001]
  • [Cites] Cancer Immunol Immunother. 1995 Aug;41(2):111-21 [7656270.001]
  • [Cites] Blood. 1995 Dec 15;86(12):4422-9 [8541530.001]
  • [Cites] Exp Hematol. 1995 Dec;23(14):1543-52 [8542945.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1303-8 [8640818.001]
  • [Cites] J Immunol. 1996 May 1;156(9):3486-92 [8617977.001]
  • [Cites] Blood. 1996 May 1;87(9):3984-92 [8611731.001]
  • [Cites] Eur J Haematol. 1996 May;56(5):301-7 [8641404.001]
  • [Cites] Bone Marrow Transplant. 1996 Jan;17(1):101-9 [8673041.001]
  • [Cites] J Exp Med. 1996 Jul 1;184(1):159-64 [8691129.001]
  • [Cites] Bone Marrow Transplant. 1996 Jul;18(1):53-61 [8831996.001]
  • [Cites] Leukemia. 1996 Dec;10(12):1975-9 [8946940.001]
  • [Cites] Bone Marrow Transplant. 1997 Jan;19(2):161-72 [9116614.001]
  • [Cites] J Leukoc Biol. 1997 May;61(5):583-91 [9129207.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2288-95 [9196142.001]
  • [Cites] Blood. 1997 Jul 1;90(1):453-63 [9207483.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2830-8 [9326252.001]
  • [Cites] Hematol Cell Ther. 1997 Oct;39(5):252-6 [9395899.001]
  • [Cites] Blood. 1998 Jan 1;91(1):347-52 [9414304.001]
  • [Cites] Blood. 1998 Apr 1;91(7):2588-600 [9516161.001]
  • [Cites] Bone Marrow Transplant. 1998 May;21(9):909-16 [9613783.001]
  • [Cites] Br J Cancer. 1998 Jun;77(12):2291-7 [9649148.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5344-7 [9850063.001]
  • [Cites] Bone Marrow Transplant. 1999 Jan;23(1):53-62 [10037051.001]
  • [Cites] Bone Marrow Transplant. 1999 Feb;23(4):335-46 [10100577.001]
  • [Cites] J Interferon Cytokine Res. 1999 Apr;19(4):351-60 [10334386.001]
  • [Cites] Bone Marrow Transplant. 1999 Jun;23(11):1123-9 [10382951.001]
  • (PMID = 17570320.001).
  • [ISSN] 1567-5769
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA72781; United States / NCI NIH HHS / CA / CA61593; United States / NCI NIH HHS / CA / R01 CA061593-04; United States / NCI NIH HHS / CA / R29 CA072781; United States / NCI NIH HHS / CA / CA072781-02; United States / NCI NIH HHS / CA / R29 CA072781-04; United States / NCI NIH HHS / CA / R01 CA072781-07; United States / NCI NIH HHS / CA / CA072781-03; United States / NCI NIH HHS / CA / CA072781-04; United States / NCI NIH HHS / CA / R01 CA061593; United States / NCI NIH HHS / CA / R01 CA072781; United States / NCI NIH HHS / CA / CA061593-04; United States / NCI NIH HHS / CA / CA072781-05; United States / NCI NIH HHS / CA / R29 CA072781-03; United States / NCI NIH HHS / CA / R29 CA072781-02; United States / NCI NIH HHS / CA / CA072781-07; United States / NCI NIH HHS / CA / R29 CA072781-05
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, Thy-1; 0 / Interferon-alpha; 0 / Interleukins; 0 / RNA, Messenger; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS26823; NLM/ PMC2034447
  •  go-up   go-down


94. Vonderheide RH, Dutcher JP, Anderson JE, Eckhardt SG, Stephans KF, Razvillas B, Garl S, Butine MD, Perry VP, Armitage RJ, Ghalie R, Caron DA, Gribben JG: Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol; 2001 Jul 01;19(13):3280-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Patients with advanced solid tumors or intermediate- or high-grade non-Hodgkin's lymphoma (NHL) received rhuCD40L subcutaneously daily for 5 days in a phase I dose-escalation study.
  • Grade 3 or 4 transaminase elevations occurred in 14%, 28%, and 57% of patients treated at 0.05, 0.10, and 0.15 mg/kg/d, respectively.
  • Two patients (6%) had a partial response on study (one patient with laryngeal carcinoma and one with NHL).
  • For the patient with laryngeal cancer, a partial response was sustained for 12 months before the patient was taken off therapy and observed on no additional therapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. CD40 Ligand / pharmacology. Lymphoma, Non-Hodgkin / drug therapy. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antigens, CD19 / drug effects. Antigens, CD4 / drug effects. Chemical and Drug Induced Liver Injury. Female. Humans. Injections, Subcutaneous. Lymphopenia / chemically induced. Male. Maximum Tolerated Dose. Middle Aged. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2001 Dec 1;19(23):4351-3 [11731523.001]
  • (PMID = 11432896.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD4; 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 147205-72-9 / CD40 Ligand
  •  go-up   go-down






Advertisement